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ABSTRACT OF THE DISSERTATION 
 
CERVICAL INFECTION WITH HIGH-RISK HUMAN PAPILLOMAVIRUS 
 
ANOGENITAL SUBTYPES IN INDIGENOUS WOMEN IN  
 
ALTA AND BAJA VERA PAZ, GUATEMALA 
 
 
by 
 
Anne Jeffries 
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Miami, Florida 
 
Professor Consuelo Beck-Sagué, Major Professor 	
Cervical cancer, caused by oncogenic (high risk [hr]) human papillomavirus (HPV) 
subtypes, is the most common cancer in women in Guatemala and the most common 
cause of cancer mortality in women aged 15-44 years. Visual inspection with acetic acid 
(VIA) with onsite cryotherapy “test-and-treat” is recommended for underserved 
Guatemalan indigenous rural women. This research assessed: 1) hrHPV infection 
prevalence in women screened by VIA; 2) Sensitivity and specificity of VIA in detecting 
hrHPV infection and cytologically identified precancerous and cancerous lesions; and 3) 
Factors associated with hrHPV infection. Analysis of anonymous data collected during 
VIA clinics in 2013 (N = 205) and 2017 (N = 234) for indigenous women aged 21-65 
years in six villages showed 22.6% (95% confidence interval [CI]=18.7%-27.2%) had 
hrHPV cervical infection. VIA results were abnormal in 5.9% (95%CI=3.8%-8.8%). 
Only nine VIA exams in 89 women with hrHPV were abnormal (Sensitivity=10.1%, 
95%CI=4.7%-18.3%), although abnormal VIA was associated with hrHPV (Prevalence 
viii 	
Ratio [PR])=1.8; 95%CI=1.1-3.1; P=.05).  Of 221 women who had VIA, hrHPV nucleic 
acid testing and liquid preparation cytology (equivalent to Papanicolaou or “Pap”) 
testing, 10 (4.7% [95%CI=2.3%-8.5%]) had abnormal cytological results, including one 
cancer, four high- and five low-grade squamous intraepithelial lesions. VIA sensitivity 
and specificity for detection of precancerous cytological abnormalities and cancerous 
lesions were 20.0% (95%CI=2.5%-55.6%) and 96.0% (95%CI=92.3%-98.3%) 
respectively. In contrast, hrHPV sensitivity and specificity were 100% (95%CI=71.7%-
100%) and 88.7% (95%CI: 83.9%-92.7%). In both years combined, women aged fewer 
than 29 years or reporting fewer than four pregnancies were more likely to have hrHPV 
cervical infection (36.8%, 27.3%, respectively) than those who were older or reported 
more pregnancies (18.7; <.0001 and 17.9%; P=.025, respectively); 60.0% reported some 
form of modern contraception. Progesterone injections or implant users were more likely 
to have hrHPV infection (31.9%) than women using other or no contraceptives (19.5%); 
PR=1.6; 95%CI=1.1-2.4; P=.01). These data suggest that VIA may not be sufficiently 
sensitive for use in cervical cancer screening. “Test-and-treat” screening using hrHPV 
real-time testing, as recommended by the World Health Organization may be preferable 
to VIA, and may be acceptable using self-collected specimens.  
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I. INTRODUCTION 
Background 
 Cervical cancer is one of the most studied and best-understood malignancies. 
 Cancer producing (“high-risk” or oncogenic) human papillomavirus (hr-HPV) subtypes 
are recovered in 95%-100% of cervical cancer specimens and hrHPV infection has been 
identified as a necessary element in most cases of cervical carcinoma1-11.  Although 
cervical cancer is one of the most preventable and treatable cancers, it remains a leading 
cause of cancer mortality in women worldwide2,4,6-9,12-16. In high-income countries, 
cervical cancer morbidity and mortality have dramatically declined due to the use of 
cytological screening with Papanicolaou (pap) “smears” and timely treatment. Cervical 
cancer screening with cytology has been considered standard-of-care for decades; at least 
75% of women participate in cervical cancer screening in high-income countries15. At 
present, 81%-87% of new cervical cancer cases and deaths are believed to occur in low- 
and middle-income countries (LMICs)2,4-9,12-16, in which women have limited access to 
needed screening. Guatemalan indigenous women are at particular risk for cervical 
cancer due to their marginalization, yet there is no registry for indigenous people and 
cancer rates in Guatemalan indigenous people, who represent greater than 50% of the 
population17. 
Statement of the Problem 
The Latin American and Caribbean (LAC) region is home to just nine percent of 
the world population, but bears approximately 16% of the world burden of cervical 
cancer mortality18,19. Lack of infrastructure to provide care, including screening and 
follow-up, and poverty, creating marginalized populations in low-income countries, 
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perpetuate barriers to health care access. According to a 2011 Pan-American Health 
Organization (PAHO) report “by the year 2030, cervical cancer is expected to kill over 
474,000 per year, 95% of these deaths in low-and middle income countries20”, an 
apparent result of low access to screening, diagnosis and effective treatment. Guatemala 
is a middle-income country plagued by inadequate healthcare infrastructure, endeavoring 
to provide service to remote indigenous populations. In LMICs, a highly promoted 
strategy for low-cost cervical cancer screening is visualization and inspection with acetic 
acid (VIA). VIA is often performed as part of cervical examination with magnification 
using colposcopy. In LMICs, it is used in conjunction with immediate treatment with 
cryotherapy in a “see-and-treat” exam. Colposcopy uses magnification for biopsy and 
curettage of tissue within the cervical os. The biopsies and endocervical tissue from the 
curettage are examined for cellular changes. The results of the tissue histopathology 
guide treatment decisions. In contrast, VIA relies exclusively on examiner’s naked-eye 
assessment, so training is vital. The judgment to treat is based on the unmagnified exam, 
with no laboratory validation. Cryotherapy as a treatment for precancerous lesions is not 
entirely without risk, but generally is well tolerated. Initial side effects can include watery 
discharge, pelvic pain, vaginal bleeding and potentially infection. Risks include infection, 
obliteration of the cervical transformation zone and stenosis of the cervical os, 
complicating future evaluations. The benefit of immediate treatment may be outweighed 
by the difficulty in establishing continuity of care, and follow-up over years, an essential 
component that has decreased mortality in high resource countries.  
3 	
 
Significance of the Study 
Little is known of the prevalence of high-risk HPV subtype infection in rural 
indigenous women in Guatemala21. or the effectiveness of low-cost screening techniques, 
such as VIA, currently used to identify women with precancerous and cancerous 
lesions22-24.   However, there is growing concern about the acceptability and efficacy of 
VIA in Guatemala, due to country-specific training and competence issues and issues 
related to VIA itself24.  
Current Study Aims 
The objectives of this research are to: 
1. Estimate the prevalence of high-risk anogenital HPV-subtype cervical 
infection in Alta Vera Paz, rural Guatemala; 
2. Evaluate the sensitivity and specificity of VIA in detection of clinically 
significant cervical infection with high-risk anogenital HPV-subtypes using as 
the gold standard nucleic acid high-risk subtype-specific HPV testing and 
liquid-based cytology (equivalent to Papanicolaou or “Pap smears”); 
3. Identify factors associated with hrHPV infection in the indigenous female 
population in the Alta and Baja Vera Paz regions of Guatemala.  
The overarching goal of this research is to evaluate the gaps between screening 
and effective treatment of precancerous and cancerous lesions in rural Guatemala, 
interventions to eliminate those gaps and efforts to reduce the substantial preventable 
HPV-associated mortality in the region. Evaluation of VIA requires simultaneous 
collection of samples HPV DNA hybrid testing, cytology and or biopsy, and the 
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laboratory technology to conduct these tests. Lack of laboratory availability is already 
identified in Guatemala as a deficit, and the healthcare infrastructure has no method for 
follow-up24 or patient tracking. Therefore there has been little opportunity to validate the 
results of VIA in rural Guatemala and determine if the exam is likely to reduce the 
mortality associated with cervical cancer. 
Hypotheses: Based on literature review and preliminary studies, we hypothesized that: 
1. High-risk HPV-subtype cervical infection prevalence in the study population will 
exceed 20%. 
2. “Real world” sensitivity of VIA to detect active infection with high-risk HPV 
subtypes will be lower than published estimates of 30%-40%.  
3. Cervical cancer screening in rural Guatemala with HPV testing would be 
improved by hrHPV testing with onsite same-visit (“real-time”) results.  
This research compared VIA results to hrHPV and state-of-the-art cytological 
testing and assessed the prevalence of hrHPV infection in the Vera Paz regions in 
Guatemala. Analysis of de-identified data collected during VIA clinics during which 
hrHPV testing was performed allowed assessment of hrHPV prevalence, and estimation 
of sensitivity and specificity of VIA screening vs. hrHPV testing and cytological 
evaluation. This study assessed prevalence in the Vera Paz region of Guatemala. Previous 
to this research, a study by Valles25 et al in 2009 in Escuintla, Guatemala, showed high 
hrHPV prevalence.  
  A secondary analysis of data collected to compare VIA with cytology and hrHPV 
screening assessed the sensitivity and specificity of VIA during free VIA clinics in rural 
communities in the Vera Paz regions of Guatemala. There have been no previous studies 
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of this kind assessing VIA in the field in rural Guatemala indigenous persons outside of 
urban settings. 
  The referral of patients to specialized diagnostic and treatment facilities is 
informal, and is reliant on patient initiative and adherence. Chary26, 2015 published her 
study following women within INCAN (Instituto Nacional de Cancerología [National 
Institute of Cancer] the National Cancer Hospital in Guatemala City), as they navigated 
their way through the system for care. Rural indigenous women have identifiable barriers 
to general and particularly specialized care including travel time and cost, loss of work 
and care of family during absence; this unique community has cultural perspectives and 
historical relationships with the non-indigenous population that must be considered. Even 
once in care, equipment and medications are often unavailable, broken or too expensive. 
Memory of Silence, a document mandated by the Peace Accords in 1994, was 
completed by the Commission for Historical Clarification, an impartial record, obtained 
through survivor testimony, of the human rights abuses perpetrated upon the Mayan 
people and communities over the three decades of civil conflict in Guatemala27. The 
document describes the military dictatorship’s agenda of instilling fear of the government 
and exerting control of Mayan communities through use of torture, rape and 
disappearances, sometimes forcing indigenous persons to perform these acts against other 
community members. Loss of the communities and culture is evident today in the 
decreased use of traditional dress, an external declaration of ethnicity. The Justice system 
lost credibility as it ignored human rights violations inflicted on civilians by the 
Guatemalan military.  
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The deep shortage of resources and opportunity in Guatemalan rural indigenous 
communities reflects worldwide historical and contemporary inequities28. Discrimination 
toward the indigenous people and poor access to preventive health care are compounded 
by the gender inequality and violence experienced by indigenous women29 which are 
associated with increased risk for cervical cancer30.	
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II: LITERATURE REVIEW 
 
Theoretical Foundation: Theory of Gender and Power 
The theories that inform this analysis are the Theory of Gender and Power1 
(Figure 1) and the Theory of Planned Behavior (Figure 2)1. Women in Guatemala have  
 
10 	
long been subject to male dominance, and to a lack of women’s health infrastructure and 
contraception services2. The Theory of Gender and Power examines a woman’s capacity 
on three levels. The first (Division of Labor), in Guatemala strongly favors men. Income 
inequality is related to education inequity2,3 only 39.9% of rural indigenous women are 
literate and of those, nearly 80% have attended school an average of three years3,4 while 
53.3% of rural indigenous men are literate3. Guatemalan women bear most of the 
responsibility in raising children and Guatemala has one of the highest fertility rates in 
Latin America and the Caribbean (LAC) (Figure 3)5. Total fertility rate is directly and  
Figure 3. Cervical cancer incidence and mortality, by total fertility rate, 23 selected 
countries, Americas Global Initiative for Cancer Registry Development, 2012, and Total 
Fertility Rate, WHO. 
	  
strongly significantly associated with cervical cancer incidence (p = .0075) and cervical 
cancer mortality (p=.0079). 
Childbearing and childcare responsibilities also limit their access to employment 
and higher parity is associated with increased risk for cervical cancer6,7. Poverty is a 
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recognized risk factor for cervical cancer8,9, and nearly 71% of the rural population of 
Guatemala lives in poverty8.A majority of indigenous women work in home farming, a 
primary source of food and income, yet only 26% farm family-owned land – and that is 
generally owned with their husband10. Farming and care of animals and wood gathering 
are primarily women’s responsibility, not income generating. It is estimated that women 
contribute four-fold what men contribute in domestic work3, 86% of households rely on 
wood as fuel, which contributes to the degradation of natural resources, perpetuating the 
poverty cycle. Wood burning for cooking exposes the women to smoke, which is 
suspected of not only promoting respiratory illness but also increasing risk of cancers10. 
 The Sexual Division of Power in the theory is manifested by the violence against 
women in Guatemala. The death rate resulting from violence against women in 
Guatemala, the third highest in Latin America in 201211-13, perpetuates a vulnerable 
female society. The Guatemala Human Rights Commission has investigated the roots of 
this violence, with the civil war contributing a component11. Indigenous women suffered 
extreme violence at the hands of the government forces12-14. During the civil war, rape 
and torture were used to terrorize the indigenous population13-16. Contemporary research 
indicates organized crime and gang activity also perpetrate violence against women2, 
perpetuating misogynistic attitudes. These are exacerbated by government indifference in 
prosecuting these crimes2,11,12 continuing the cycle. It is estimated that partner 
violence2,11,12 is an important cause of femicide (gender-based homicide). Domestic 
violence was the suspected cause of 61% of the femicides in Guatemala in 200811.  
Perpetrators of violence against women have enjoyed impunity, with less than 2% of 
cases involving violent deaths of women prosecuted between 2005 and 20072,11,12. Child 
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abduction and forced prostitution of girls and women also contributes to the violence 
against women and increased risk of cervical cancer2,16,17. 
The Theory of Gender and Power offers a core interpretation of relationships 
within a culture based on the sociopolitical concept of gender, as distorted by combined 
forces of government-endorsed, extrajudicial and criminal violence1,17,18 (Figure 1). This 
structure controls opportunities afforded to women, and their subjugation within 
communities that are themselves are intensely subjugated. Community structures 
establish social norms and religious beliefs that serve to control relationships within 
patriarchal frameworks1. The restrictions of working within the home to support the 
family, and selling produce in the local markets limit women’s economic power. Lack of 
health care access and negative societal concepts regarding contraception (religious 
prohibitions, and understanding of contraception as a form of government population 
control in the context of genocidal efforts) may be constraining forces on women’s 
personal fertility control and autonomy. Infrastructure deficits in health care access 
constitute an institutional discrimination, accepting indifference to women. Unprosecuted 
femicide tacitly communicates the appropriateness of violence towards women, and 
misogynistic paradigms isolate women from justice and political power. Indigenous 
people have struggled to gain respect and trust the government following the civil war, 
but there is deep-seated mistrust of governmental services14,15, both judicial and service-
related, that isolates indigenous women from self-realization. Women in Guatemala have 
multiple challenges in seeking health care: poverty, isolation, disrespect of their ethno-
identification and deficient social programs to promote literacy and economic security8. 
13 	
 
Theory of Planned Behavior 
The Theory of Planned Behavior (Figure 2) explains issues related to women’s 
ability to learn about and incorporate cervical cancer screening into their lives, and how 
the community of women at risk accepts pelvic exam, and understands and acknowledges 
personal risk. The Theory of Planned Behavior1,19,20  is an extension of the Theory of 
Reasoned Action21 and posits that intentions predict behaviors, that is, intentions are 
predicted by attitudes toward the behavior and subjective norms about the performance of 
the behavior, and extends the Theory of Reasoned Action to include perceived behavioral 
control. Specifically, the Theory of Planned Behavior suggests that intentions are 
predicted by attitudes toward the behavior and subjective norms about the performance of 
the behavior22. The Theory of Planned Behavior suggests that, provided support for their 
health care seeking, and educational efforts to encourage self-protection, if not self-
realization, women can change the subjective community norm.  
Low levels of control may politically and economically increase indigenous 
Guatemalan women’s risk not only for physical violence but also for conditions like 
reduced access to cervical cancer screening, diagnosis and effective treatment23. 
Understanding the communities, power structure, and health behaviors related to access 
and education can open the dialogue to health literacy, but the overwhelming poverty 
must be addressed to provide greater autonomy to the people and women in particular. 
Paul Farmer writes “…inequities have powerfully sculpted not only the distribution of 
infectious diseases, but also the course of disease in those affected”23. Writing about 
emerging infectious diseases, his statements apply to cervical cancer, recently recognized 
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to be a chronic infection, “An implication, clearly, is that one place for disease to hide is 
among poor people, especially when the poor are socially and medically segregated”23. 
This certainly typifies the situation in Guatemala, where death from cervical cancer is not 
recorded in vital records24,25 and the actual toll on women is extrapolated, not determined. 
Reliance on health promoters from within indigenous communities provides a construct 
through which women can begin to understand the concept of screening for cervical 
cancer, and normalizes pelvic exams26. As rural indigenous women are educated to 
understand the risk of cervical cancer, they can accept and promote screening, as access 
is made available through the NGOs offering care. This, in the lens of the Theory of 
Planned Behavior, evolves into intention to seek care through improved access, and 
community acceptance of the exam, facilitating for the health care seeking behavior.  
Cervical cancer is a daunting burden on both social and economic sectors of 
Guatemala. Control of cervical cancer in Latin America has been for the most part 
unsuccessful9,27. Herrero et al.28 estimate that even if incidence rates are not increased, 
there would be an increase in case numbers solely based on the population aging.  The 
screening programs that have curtailed cervical cancer deaths in high-income countries 
involve technical procedures, laboratory access, and consistent follow-up generally 
regarded as too complex and expensive for poor communities countries like Guatemala 
indigenous populations8. Nevertheless, the success of antiretroviral scale-up in low- and 
middle-income countries worldwide, with plunging HIV-related mortality rates, 
particularly in LAC, have sparked interest in offering technically complex interventions 
in these countries, particularly to cancer patients29-32. Pursuit of technically advanced but 
highly acceptable women’s health care and cervical cancer prevention and treatment in 
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Guatemala should be pursued, within the context of the experience of the indigenous 
women. Attentiveness to their need to have an understanding of the process respectfully 
provided in their language, and with consideration of the historical and cultural gender 
discrimination suffered, suggests that help must be sought from within the communities 
to introduce the most effective interventions in the most acceptable way.  
The Theory of Planned Behavior builds a base of education and local support for 
women to structure an understandable and practical design for provision of their care. As 
noted in rural Peru33 predictors for participation in screening programs included: knowing 
a woman who had participated in VIA, having a supportive partner, having attended an 
educational session concerning cervical cancer and having a satisfactory experience with 
the health care system. Deterrents to participation included having a partner who does not 
condone the exam, a poor experience interacting with the health care system, and belief 
the exam was detrimental to her. 
The lack of control politically and economically2, 34 increases indigenous 
Guatemalan women’s risk for not only for physical violence but also for reduced access 
to cervical cancer screening, diagnosis and effective treatment. Understanding the 
communities, the power structure, and health behaviors related to access and education 
can open the dialogue to health literacy, but the overwhelming poverty and unacceptably 
low access to care must be addressed18,36-37.   
Natural History of Human Papillomavirus (HPV) Infection 
 There is an abundance of literature describing the natural history of HPV since 
even before the association/presence of HPV was noted in cervical cancers, when 
screening techniques such as the Papanicolaou cytology (“pap smear”) and diagnostic 
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approaches (e.g., biopsies under colposcopy) first suggested the sexually transmitted 
nature of cervical cancer38,39. The current understanding of the natural history of HPV 
further informs the protocols used in screening. The Bethesda terminology38 classifies the 
lowest level of high-risk hrHPV subtype infection detectable by cytology (microscopic 
assessment of samples obtained by pap or liquid preparation) as the squamous 
intraepithelial lesion (SIL), low or high-grade, and describes the progression of lesions to 
carcinoma in situ, defined as malignancy before metastasis (malignant spread) (Table 1).   
Table 1 2014 Bethesda System for Reporting Results of Cervical Cytological 
Examination 
Squamous	Cell:	
NILN:	Negative	for	intraepithelial	lesion		
ASC-US	-	Atypical	squamous	cell	undetermined	
significance,	reported	with	hrHPV	+/-	
ASC-H	-	Atypical	squamous	cells,	cannot	exclude	
high	grade	lesion	
LSIL	–	Low	grade	intraepithelial	lesion,	mild	
dysplasia/CIN	1	
HSIL	–	High	grade	intraepithelial	lesion.	
Moderate/severe	dysplasia/	CIN	2,	3	
CIS	–	Carcinoma	in	situ	
SCC	–	Squamous	cell	carcinoma	
Glandular	Cell:	
Atypical	-	Endocervical	cells	–	favor	neoplastic,	
glandular	cells	–	favor	neoplastic	
Endocervical	adenocarcinoma	in	situ	
Adenocarcinoma-	specified	as	endocervical,	
endometrial,	extrauterine. 
NILN	
	
SCC	
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of squamous cell or endocervical adenocarcinoma type38.  An initial cellular change, 
atypia, is a diagnosis for which pathological determination of cause by HPV co-testing is 
recommended and if positive, closer follow-up is appropriate. This grading of lesions 
requires laboratory sophistication and technique rarely available to women in rural areas 
in low- and middle-income countries (LMICs); in high-income countries, the grading and 
location of the lesion dictates the treatment protocol39. LSIL is considered an acute 
infection phase, often cleared by immunocompetent women, while HSIL represents a 
chronic infection and cellular changes, precursor to cancer. Gavitt and Winer40 examined 
serum antibodies along with vaginal/cervical HPV detection; their research supports a 
reactivation of prior infection in older women rather than newly acquired infection. They 
also found an association of viral detection with the menstrual cycle, suggesting potential 
effects of menopause on reactivation of the virus41. 
Over 100 subtypes of HPV exist, 40 of which are associated with the anogenital 
tract41-49. “High risk” (hrHPV) subtypes, those that can cause malignancies, can establish 
persistent infections, causing a disruption of the normal maturation of cells in the  
epithelial layers by proliferation within the squamocolumnar junction (SCJ)40-44,50 (Figure 
4). The SCJ, is also called the transformation zone, where epithelial cell transition occurs, 
from resistant squamous cell epithelium (consisting of multiple layers of tough cells) to 
the much more susceptible single-cell layer of columnar cells. Over 90%  
 of lower genital tract cancers arise in the SCJ (Figure 4)39,50. It is thought that the virus  
enters basal cells below the columnar cells via micro-abrasions. As HPV infects the 
cervical cells, it causes the host to replicate HPV. With the help of the host cells’ normal 
shedding, more viral particles are released39-42. Once integrated into the host, these genes 
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Figure 4. Coronal section diagram of cervix (A) and microscopy (B) from Herfs et al. 
PNAS. 2012; 10516-21. 
 
enter basal cells below the columnar cells via micro-abrasions. As HPV infects the 
cervical cells, it causes the host to replicate HPV. With the help of the host cells’ normal 
shedding, more viral particles are release39-42. Once integrated into the host, these genes 
disrupt normal cells by binding to and inactivating tumor suppressor proteins39-42. Fifteen 
HPV subtypes are classified as oncogenic; HPV 16 is thought to be present in nearly 50% 
of cervical cancers and HPV 18 is responsible for an additional 10%-15%39-42,48,49. 
Most women with normal cell-mediated immunity clear the active infection but the 
infection can persist latently for decades42-46. The typically years-long natural history of 
oncogenic HPV subtype infection in immunocompetent persons, and its typically slow 
progression to malignancy, allows for intermittent screening. Generally, women aged 
mid-thirties to fifties begin to exhibit cellular changes that progress to cancer. The 
general population testing in Escuintla department in Guatemala by Valles25 in 2009 
demonstrated an increase in hrHPV infection in women over 35 years of age. Such 
changes are thought to be related to reactivation of the virus associated with changes 
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related to menopause or immunity and even potential exposures by either new sexual 
partners or long-term partners’ new sexual partners40. Cervical cancer is associated with 
persistent infection, the course of which is influenced by viral genetics, host immune 
response and related cofactors (e.g., HIV infection, malnutrition)42. Behavioral factors are 
known to have the least influence with only a 1.5-2 fold increase in developing pre-
cancer after an infection with hrHPV Once integrated into the host, these genes disrupt 
normal cells by binding to and inactivating tumor suppressor proteins39-42.  Once 
integrated into the host, these genes disrupt normal cells by binding to and inactivating 
tumor suppressor proteins39-42. 52-58. Considering the modest impact of behavioral risk 
factors, a woman’s risk of progression to cervical cancer is dependent upon not only her 
behavior but that of her husband or partner’s.  
The rapid acquisition of infection with an anogenital HPV subtype following 
sexual debut59-62, 28.5% of women test positive for hrHPV subtypes within one year of 
their sexual debut61, suggests that screening and treatment programs must address the 
latency and potential reactivation of the infection. The reality is that most HPV infections 
are spontaneously resolved39,43-45,63-65 and do not reactivate and progress to cervical 
cancer, suggesting that overtreatment may occur if cytology and determination of the 
degree of lesion to be treated are unavailable. The mere presence of hrHPV in the genital 
tract does not in itself suggest inevitable progression to cancer for young 
immunocompetent persons, which again points to the importance of infrastructure that 
allows for follow-up, and laboratory sophistication to “grade” a lesion prior to 
treatment35,64,65.  
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Evaluation of Cervical Cancer Screening Tests 
 Screening is a process designed to detect disease processes before they become 
symptomatic, and typically precedes a definitive diagnosis66. Screening tests reduce the 
number of persons that must be tested to make a definitive diagnosis, generally by 
identifying a population at higher or highest risk. Screening generally uses a highly 
sensitive test to identify the sub-population most likely to have the disease process. A 
more specific test to identify the “true” cases of the condition (“confirmatory” test) often 
follows the screening tests. Screening tests are evaluated by what percent of persons with 
a positive “gold standard” test they detect (test “sensitivity”) and “specificity” (the 
percent of persons in whom a “gold standard” test has ruled out the condition that test 
negative on the screening test). Sensitivity and specificity are test characteristics. The 
predictive value of a positive or negative screening test is affected by the prevalence of 
true positives in a population. The predictive value of a negative test (proportion of 
negative screening tests that occur in persons that are truly negative) and predictive value 
of a positive test (proportion of positive screening tests that occur in persons that are truly 
positive) assess screening test performance at specific population levels. In populations 
with very low prevalence of the condition for which persons are being screened, even 
tests with very high specificity will have low positive predictive values.    
Cervical Cancer Screening in Low Income and Middle Income Countries 
 To assess and address cervical cancer in underserved and low-resource 
populations, VIA has been proposed28,64,65, 67-71. Hinselmann, who experimented with 
VIA in 1924, first studied the cervix using acetic acid, which is known to whiten 
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precancerous and cancerous lesions72. VIA developed into colposcopy when 
magnification improved the technique. During colposcopy, biopsies of lesions are taken 
for diagnosis and to “stage” lesions, determining disease progression, as Hinselmann’s 
research demonstrated that visualization alone was not sufficient to diagnose 
precancerous lesions or cervical cancer71. This technique is used to confirm pathology 
and direct treatment as needed. Colposcopy became widespread in medical practice in the 
1960s-70s. In the 1990s found many LMICs resorted to VIA as a screening technique, 
revisiting historic development of screening approaches of cervical cancer. The minimal 
need for equipment and immediate results were believed to meet the needs for screening 
for low-resource settings. However the accuracy of VIA remains difficult to assess.  
Denny et al.73 in 2002 compared VIA to VIA with magnification and cytology in 
South Africa. There was minimal difference in sensitivity of direct visualization and 
enhanced view with magnification. Both had negative predictive values of 94.4%-97.2% 
in all lesion categories (high- or low-squamous intraepithelial lesion) as did cytology 
(94.5%-96.5%). The positive predictive value of the cytological examination was 34.5%, 
whereas VIA had a positive predictive value of 12.9%-13.7%. The subjectivity of the 
test, improper application of acetic acid and poor visualization of the cervix were offered 
as explanations for lesion detection failure in VIA. In 2005, Sarian, et al.74 as part of the 
Latin American Screening study assessed the performance of VIA and against 
colposcopy found a sensitivity of 45.4%-50% for HSIL. The study included hrHPV 
testing, and in conclusion discussed augmenting VIA with hrHPV screening, following 
up women testing positive with colposcopy. The authors advise that “there is no 
argument that organized cytology screening is the only cost-effective means of cervical 
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cancer control” pointing to the need to explore ways to improve access to cytology 
screening within a context linkage of patients with suggestive results to specialized care. 
In Peru, Jeronimo et al.69 in 2005 compared VIA to pap smear using colposcopy as the 
gold standard, and determined positive predictive value of both VIA and pap smears to be 
under 10%. It is noted that the providers performing the pap and VIA exams were 
oncologists69. Yet in the discussion portion, the authors state “VIA…requires a low level 
of training”69. The study does confirm the benefit of immediate results with VIA, noting 
that 26.3% of women with abnormal pap were lost to follow-up in contrast to 2.3% of 
women with an abnormal VIA. Herrero et al.28 examined screening methods in two Latin 
American countries. In Costa Rica, liquid-based pap, conventional pap and HPV testing 
were compared; liquid-based pap was shown to have sensitivity/specificity of 
87.5%/87.8% compared to pap smear as the gold standard, and 63%/93.7% and HPV 
testing at 85.3%/88.2%. All the tests had a >99% negative predictive value, with positive 
predictive value of 11.5% for conventional pap, 8.5% for HPV testing and 9.0% for the 
liquid-based pap. Costa Rica developed a National Cytology Laboratory during the 
reorganization of the cervical cancer-screening program and since noted a decline in 
incidence and mortality from cervical cancer. Costa Rica committed resources into 
establishing infrastructure for diagnostics and treatment, which improved continuity of 
care. In Peru, VIA had similar results: HPV testing was the most sensitive (89.7%) 
however prevalence of abnormal cytology was noted to increase with age while hrHPV 
positivity decreased. Examiners were trained midwives, and over the course of the study, 
false positive VIA decreased with experience, demonstrating subjectivity in the exam, 
need for practice, and little evidence of VIA being technically “extremely simple”. The 
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study discussed cytology, hrHPV testing and VIA, and concluded that VIA was 
appropriate where no other screening options were available but that any program of 
screening must include referral for specialized care. The study in Peru was part of a 
project to increase coverage of screening (TATI project75).  An adjunct of the TATI study 
by Alamonte76 was situated in a remote area of Peru, and found that the conditions under 
which the testing occurred were more apt to reflect the usual conditions in which routine 
screening was taking place. Both VIA and pap smears performed below expectations 
compared to other studies; routine cytology (pap smear) was ineffective for screening due 
to inadequate laboratory quality which also was reflected in the liquid-based cytology. 
Cytology has been proven in high-income countries to be sufficient for screening, but 
considerable investment in laboratory facilities and technician expertise must be made 
before this screening option will be useful in LMICs. Costa Rica is an example of a 
country where such investment has been made with promising results. Sherris71 in 2009 
reviewed studies that compared VIA with cytology and colposcopy, noting that rural Peru 
found a sensitivity of 26% for conventional cytology in the region, revealing the 
unacceptable sensitivity of pap smear for screening in this setting. The Latin American 
Screening77 study was conducted in Brazil and Argentina, also comparing VIA with 
cytology in four cities (three in Brazil and one city in Argentina). Researchers found a 
similar prevalence of hrHPV in the four cities ranging from 15.4% to 18.8%. There were 
higher rates of insufficient sampling with the conventional pap compared to liquid-based 
cytology, which would require a second visit to clinic to repeat the test. The authors 
advise that “there is no argument that organized cytology screening is the only cost 
effective means of cervical cancer control” pointing again to a failure of infrastructure. A 
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meta-analysis by Sauvaget et al.78 in 2010 reviewed 26 VIA studies in which women had 
confirmatory tests to determine the accuracy of VIA in screening, finding a sensitivity 
ranging from 41%-92% (pooled sensitivity=80%). Specificity ranged from 49%-94%. 
Only two of the studies were in Latin America. The studies that involved VIA compared 
to colposcopy did not always confirm findings by histopathology, avoiding biopsies of 
women with negative screening tests. In a study in Nigeria79, pap and VIA had 
sensitivities of 60%, and specificities of 100% and 94.9%, respectively. In this study, the 
risk of overtreatment was preferred over the risk of loss to follow-up, again considering 
infrastructure as a necessary component in a successful screening program. In 
Colombia80, mortality from cervical cancer was evaluated based on five variables: 
women who reported yearly screening, women who did not receive results of cytology, 
women with abnormal results who followed up for treatment, women who never had 
cervical cytology and uninsured women. Increased screening coverage did not decrease 
cervical cancer mortality in uninsured women. After adjusting for insurance coverage, 
compliance with follow-up visits was associated with a 40% reduction in mortality. 
Wright and Kuhn81 reviewed efforts in LMICs, finding that continuity of diagnosis and 
treatment was the primary requirement in reducing mortality from cervical cancer and 
avoiding overtreatment. Studies from India and South Africa reviewed by the authors 
both indicated less disease progression in women screened and treated, if screened with 
hrHPV. It was noted that in India there was no reduction in cervical cancer incidence or 
mortality in the VIA and control arms of this prospective study81. A comparison of pap to 
hrHPV testing to co-testing in the United States by Blatt et al.82 demonstrated that co-
testing in high-income countries would improve diagnosis and treatment. In the results of 
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this study, 19% of women with cervical cancer would have been missed with hrHPV 
testing alone. Pap (alone) sensitivity was 91.3%, hrHPV sensitivity alone was 94%, and 
co-testing had a sensitivity of 98.8%. Utilizing cervical biopsy results, 14.4% of women 
with abnormal pap had a negative hrHPV test, and of those with biopsies with an HSIL 
result, 35.4% had cervical cancer. The women who were negative for hrHPV but had 
high-grade lesions or cervical cancer were older, perhaps representing longer exposure, 
lower tumor viral levels and underscoring the importance of screening older women at 
risk for cervical cancer. In another meta-analysis of screening tests for cervical cancer in 
sub-Saharan Africa, Fokom-Domgue et al.83 compared VIA with visual inspection with 
Lugol’s iodine (VILI), a solution of potassium iodine, an iodine that turns cervical 
precancerous and cancer lesions yellow) and HPV testing.  Pooled sensitivity for VIA 
was 82.4% and specificity was 87.4%. VILI sensitivity was higher than VIA and 
specificity was similar. HPV testing demonstrated a pooled sensitivity of 88.3% and 
specificity of 73.9%. The screeners preferred VILI, as the cervical mucosal changes were 
more pronounced without needing reapplication of the iodine and there was no time lapse 
before evaluation as there is with acetic acid. As with VIA, screening menopausal women 
with VILI can be inaccurate as atrophied tissue does not take up the iodine. In 2015 
Dawood and El-Tahmoudy84 also compared VIA, VILI and cytology, also demonstrating 
similar sensitivities and specificities between VIA and VILI, with cytology 
demonstrating lower sensitivity and higher specificity. Lack of access and follow-up was 
again identified as a major deficit in cervical cancer control in LMICs. The meta-analysis 
by Mustafa et al.85 also compared VIA, cytology and HPV testing, as well as 
overtreatment compared to under-treatment. Consideration of the future consequences of 
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over or under-treatment and the context of the woman being tested is an important 
measure, along with actual mortality. Sensitivity and specificity are important but 
outcomes have been difficult to measure in many LMICs.  Zhou86 retrospectively 
evaluated hrHPV test for precision in detecting high-grade cervical lesions as it has been 
considered first line screening. The sensitivities were similar to prior studies at 80.8% 
(hrHPV) and 81.2% (pap smear). False negative rates for hrHPV and pap were 8.7% and 
9.1% respectively, with co-testing bringing the false negative rate to 1.2%. When 
considering a screening test and the variables of fieldwork, the improvement in false 
negative test was important. In Zhou’s study, 37% of the women with cervical cancer had 
been hrHPV negative five years before. In 2017, Raifu87 evaluated VIA compared to 
VILI and physicians to nurses as examiners. With both tests VIA and VILI, physician 
sensitivity was higher than the nurses’ and sensitivity decreased with older participants, 
an effect that has been observed in other studies. Positivity with hrHPV reduced 
specificity yet improved both nurse and physician sensitivity, even though the result of 
hrHPV test was unknown to the examiners. Looking at participant factors, Raifu 
concluded that age, parity, and positive hrHPV increased the accuracy of the examiners. 
This study indicated that the higher-grade lesion decreased the specificity of the hrHPV 
screening test, and sensitivity decreased in the older woman screened with visual 
techniques. Age (older, post-menopausal) and high parity have been identified in studies 
as factors that increase a woman’s risk for cervical cancer7,88,89.  Age risk is explained by 
the natural history of hrHPV, the infection taking decades to reactivate, then progress to 
cervical cancer. Screening menopausal women with VIA is less effective due to the 
cervical tissue’s atrophic changes. As noted previously Guatemalan women have high 
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fertility rates, a known factor to increased the risk for cervical cancer. 
The difficulty in reviewing the accuracy of VIA includes the variations of disease 
threshold, the standards used for comparison and failure to confirm negative VIA. There 
can be discrepancies in experience and training of the VIA providers, ranging from 
physicians with experience in colposcopy to a newly trained non-physician.  
VIA does not allow for the grading of a lesion, unlike cytology, and cannot detect the 
presence of hrHPV subtypes. Aceto-whitening of the cervix can be non-specific, with 
reparative and immature squamous metaplasia also appearing white81. There is no 
protocol for confirming negative VIA exams, the ability to screen for hrHPV subtypes 
might enhance or even replace the VIA evaluation and provide better guidance for 
follow-up for women unable to access the standard cytology screening recommendations. 
Beyond studies that evaluate VIA in research settings, there has been little assessment in 
actual use, where problems associated with non-standardization of training, turnover of 
personnel, subjectivity and unavailable mentoring and continuing education potentially 
affect the quality of the screening. These factors may reduce the ability of VIA in real-
world situations to challenge the encouraging research data endorsing VIA alone as a 
screening tool.  
Treatment in Low and Middle Income Countries  
 In high-income countries, cervical cancer treatment has moved toward laser loop 
electrosurgical excision procedure (LEEP), a treatment that uses a small electrical wire 
loop to remove abnormal cells from the cervix, allowing for assessment of suspicious 
lesions, grading of the extent of invasive changes and the evaluation of borders to verify 
the complete removal of lesions90,91. High-income countries are actively eliminating 
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overtreatment by not treating low-grade lesions, observing over time, and treating only 
high-grade lesions. Cryotherapy – freezing the cervix with a probe to ablate the tissue, 
allowing for growth of tissue without the infection – was formerly an accepted treatment. 
It is no longer the treatment of choice in high-income countries due to the effects of 
freezing on cervical tissue and inability to document complete excision of the lesion and 
grade the extent of invasion. Cryotherapy causes ablation of the lesion, which may 
precludes subsequent VIA exams due to scarring of the cervical tissue and the migration 
of the transformation zone, where the SCJ lies and HPV infection proliferates, and 
narrowing of the cervical os, which create difficulty in accessing the SCJ for adequate 
sampling in later screening70,71,90. There is a theoretical risk of cervical insufficiency and 
complications of pregnancy caused by disruption of cervical tissue. Maza90 discusses 
quality of gas use in cryotherapy, comparing carbon dioxide (CO2) to nitrous oxide 
(N2O). CO2 is often easier to obtain; however, impurities can cause inconsistent 
temperatures and equipment malfunctions. Equipment requires sterilization between 
women treated, and Maza notes that it is unpredictable in number of patients who can be 
treated (2-20). Cryotherapy is indicated for treatment of precancerous lesions if 
endocervical curettage is negative, biopsy confirms disease, invasive cancer is ruled out 
and the complete lesion is visible. With VIA in LMICs, these treatment criteria may not 
be well established. 
 Moreover, the ability to immediately treat with cryotherapy provides a false sense 
of security, understating the need for continued follow-up and assessment. Schmidt et 
al.91 followed a small group of women treated with cryotherapy and found there were 
recurrences within 2 and 5 years, 24% of which were adenocarcinoma, which is more 
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difficult to diagnose and in which HPV is not always detectable. Appropriate follow-up 
with pap smear or biopsy must be incorporated into care, as recurrences should be 
anticipated if no grading of lesions is done prior to cryotherapy.  
  The complications of cryotherapy are generally mild, but can include pain, 
cramping, and watery discharge91-95. Women need to be prepared for this and for the 
recommendation for abstinence from sexual intercourse until healed. Thus, treatment 
with cryotherapy can contribute to both failure to pursue and difficulty in conducting 
future screening with VIA due to the cervical changes caused by the freezing. The 
cervical changes necessitate biopsy and a higher technical level of diagnostic capability 
that these techniques are designed to avoid91-93. Several studies in Africa and Asia have 
provided significant information regarding the use of VIA and “see and treat” programs 
offering cryotherapy. In 2012, Ziyauddin and Rajyashiri93 in India compared cryotherapy 
to LEEP. As previously noted LEEP requires electricity to perform, as well as costly 
equipment and a high level of training. It had a cure rate of 94.4% and was useful for 
diagnosis. In contrast, cryotherapy had a cure rate of 88.2% in this prospective study 
following women for one year. Even in this relatively short-term study, participants were 
lost to follow-up and four recurrences occurred in the cryotherapy treatment group of 34. 
Continued surveillance of treated women is imperative to recognize recurrence, and is a 
challenge that must be addressed with infrastructure. Cryotherapy is not indicated for 
treatment of endocervical lesions or glandular disease, neither of which can be assessed 
by VIA, but which can potentially be obscured by cryotherapy92. Failure of cryotherapy 
can be caused by inadequate freezing of the tissue because of inadequate gas pressure for 
delivery, poor probe application and insufficient time for freezing94,95. Assessment of 
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impact of VIA and cryotherapy on cervical cancer in Guatemala is desperately needed. 
 Cryotherapy is not a definitive treatment for cervical cancer, but a treatment for 
precancerous lesions; therefore, the women treated with cryotherapy as part of a “see and 
treat” intervention need to be informed that continued surveillance is needed91-95. 
Recurrence at any age is possible. The nature of the chronic infection and progression 
requires follow-up and continued care, which requires an infrastructure not currently 
available in rural communities in Guatemala.  
The global research conducted to identify strategies to decrease mortality from 
cervical cancer suggests that VIA is an acceptable screening tool, but the addition of 
hrHPV co-testing offers improvement in both sensitivity and specificity in testing for risk 
for cervical cancer and pre-cancerous lesions. No screening can be done in a vacuum; 
infrastructure to follow-up as needed and to keep records regarding testing and treatment 
is essential. Catarino et al.95 discuss the emerging technologies, as they have been trialed 
and implemented in numerous LMICs, acknowledging that hrHPV may be negative in 
the presence of a high-grade lesions, and recommend triage of women with positive 
hrHPV tests. Valles26 in 2009 estimated that in Guatemala, pap smear coverage was less 
than 10% of the vulnerable population. Winkler34 published a study on women’s 
participation in cervical cancer screening in northern Peru and identified four predictors 
of participation. These were: higher relative wealth; knowing women who have been 
screened; knowledge and use of the health care system, and having a satisfactory 
experience within the system34. This research supports the need for preventive health 
education, and community endorsement of participation in screening. Accessing care is a 
persistent barrier for poor Guatemalan women. The VIA mobile “brigades” have 
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increased awareness of the risk for cervical cancer. Now, true follow-up for diagnosis and 
treatment needs to be attainable. Self-sampling for HPV hybrid testing was studied in 
with indigenous women residing in Santiago Atitlan96. Self-sampling, which does not 
appear to reduce sensitivity, was found to be acceptable to the participants and all 
indicated they would be willing to periodically provide a sample for testing. While this 
greatly increases the simplicity of specimen collection, it still also requires a healthcare 
system that can track patients for continuity of care. 
Historical and Political Barriers 
 Guatemala has significant challenges in health care provision within the rural, 
largely indigenous communities, with infrastructure deficits traceable through a historical 
and political lens.  Guatemala’s history since Spanish colonization is steeped in political 
conflict and marginalization of the indigenous and rural populations, who suffered 
economically and witnessed the dismantling of their social/community structures during 
government-sponsored terrorism over the last three decades12-15. Prior to Spanish 
colonization of the region, Guatemala’s population encompassed 30 separate culturally 
and linguistically distinct subpopulations, most of which share the Mayan cultural 
identification12,15,97. Survival of Guatemalan indigenous people was high, as evidenced by 
the fact that they remain even after prolonged genocidal efforts, the majority of the 
Guatemalan population (51%)12-15. Linguistically distinct Mayan communities existed 
separately from the occupying structure, suffering loss of land, the primary source of 
livelihood and sustenance12-15. In the late 1890’s the country’s economy became 
internationalized through political negotiations with foreign companies, particularly the 
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American United Fruit Company13,98. This company maintained significant influence and 
power in the political arena, impacting all aspects of government activity in Guatemala98. 
 In the post-World War II era to mid-1950, there was a brief period of 
representative elected government, labor reform and redistribution of lands to the rural 
poor13,15, mostly descendants of the Mayan majority population.   This era of reform was 
brought to an end by a US CIA-backed military coup led by Guatemalan Army General 
Carlos Castillo Armas2,13-15 because of concerns of possible Communist involvement in 
the reforms. The military had long been, and again became, synonymous with the 
government, suppressing any uprising, but also forcing governmental change through 
military coups13-15. During the Armas tenure, 99.6%18 of the land that had been 
nationalized and distributed to Mayans was returned to former landowners, including 
international companies such as the United Fruit Company. The assassination of Armas 
in 1957 plunged Guatemala into a violent civil war13-15,18 which devastated the indigenous 
populations and rural poor and lasted over 30 years. The complete toll will never be 
known but an estimated 200,000 people, were killed or “disappeared”, over 80% of who 
were indigenous13-15,34. During this time, the government actively suppressed the 
education of the Mayans and their economic stability. This coincided with government 
maintenance of the status quo of poverty and illegalization of traditional Mayan healers99 
exacerbating the marginalization and weakening of the culture12-15.  
The Guatemalan Civil War, the longest and deadliest in Central America ended in 
199612-15.  The Comisión Nacional de Reconciliación (National Commission for 
Reconciliation) took the first steps toward peace in 1989, but over seven years, fighting 
continued until the accords that provided for the reconciliation between the armed forces 
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and guerrilla groups34,35 and the forging of plans for social and infrastructure reparations 
aimed at benefiting the poor, marginalized, rural, predominantly Mayan populations. Of 
the over half of the population in Guatemala documented as indigenous12,15,97, 90% of the 
population is classified as poor, or extremely poor12-15,34. The indigenous communities 
endure much shorter life expectancy at birth (17 years shorter than non-indigenous 
groups).34 
At the time of the signing of the Peace Accords, the social security system 
covered only 13% of the populations34,35,97,99 . This lack of infrastructure precluded the 
government’s accomplishment of the health care improvement provisions of the Peace 
Accords. Limitations of public health care expenditures were due to conditions of 
international debt restructuring imposed by the World Bank and International Monetary 
Fund35. The Ministry of Health (MOH) assigned the responsibility for rural health care to 
NGOs, (an estimated 10,000-15,000) working in Guatemala99-102. The Programa de 
Extensión de Cobertura (Program of Extension of Coverage, or PEC) was instituted in 
1997 to improve healthcare access to the rural populations. PEC tried to contract with 
NGOs already working in Guatemala, many of which declined participation to retain 
autonomy35 and limit association with the MOH, a government agency that, due to the 
long civil war, may have suffered from their association with the acts of the government 
and by the historical mistrust of rural citizens. Even the philanthropic and religious 
groups that had constituted the majority of NGOs in Guatemala present during the civil 
unrest, working in response to natural disasters that plagued the country, tended to be 
unwilling to accept MOH collaborations for similar reasons.  
Since PEC had contracts and funds to distribute, and philanthropic and religious 
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groups were unwilling to accept them, it turned to an entrepreneurial approach to health 
care, funding newly contracted (including for-profit) NGOs with little or no experience in 
rural health care delivery99-102. The MOH divided health care into curative and preventive 
services but did not address infrastructure deficiencies and widespread poverty that 
contributed to the failure of healthcare system initiatives15,34,99. In 2014, all contracts 
between PEC and health care NGOs were cancelled in accordance with legislation 
prohibiting the outsourcing of health care. This left a gap in care the country had no 
immediate measures to replace103.  
According to Instituto Catala d’Oncologia HPV Centre statistics published in 
2017, cervical cancer was the leading cause of female cancer and of cancers deaths in 
Guatemalan women aged 15-44, noting, however, that incidence in Guatemala is 
extrapolated from surrounding countries24. As previously noted, Valles25 published a 
study done in Escuintla, a first study in anogenital HPV infection prevalence in 
Guatemala, comparing HPV in sex workers recruited from a sexually transmitted 
infection (STI) clinic with general population HPV prevalence in women attending a 
community clinic. He found prevalence rates of 38.1% within the general population, and 
67.3% among sex workers. The prevalence of HPV for sex workers declined with age, a 
trend not seen in the general population. Persistent infection has greater potential for 
causing precancerous lesions; the authors had no explanation regarding the continued 
high prevalence in the general population. The decline in prevalence with age was 
generally noted across regions54 with a peak in the younger women as they become 
sexually active. The persistence of HPV in middle-aged women precludes once-in-a-
lifetime cervical cancer screening strategies. This study, though limited in numbers points 
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to the chronic nature of infection and potential for cervical cancer to develop in later 
decades.  
A consistent theme throughout this review is the unmet need for optimal cervical 
cancer screening. Yet this gap is also seen in access to treatment. Screening without 
treatment is unethical104 and a waste of resources. Root cause analysis would focus on 
access to screening, continuity of care and treatment. Social determinants of inequality 
include many of the characteristics of the indigenous women in Guatemala: high rates of 
poverty, lack of education, extreme gender bias and rural residency, among the factors 
that make screening for cervical cancer difficult for Mayan women in Guatemala.  
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Abstract 
OBJECTIVE: 
Determine prevalence of cervical infection with oncogenic (“high-risk” [hr]) human 
papillomavirus (HPV) in indigenous women participating in two rural visual inspection 
with acetic acid (VIA) campaigns in 2013 and 2017, and assess the sensitivity and 
specificity of VIA in detecting hrHPV infection, and predictive values of normal and 
abnormal VIA for hrHPV infection.  
METHODS: 
Analysis of anonymous data collected during VIA clinics in 2013 (N=205) and 2017 
(N=234) for indigenous women aged 21-65 years in six villages in Guatemala from 
whom specimens for hrHPV were collected at the time of VIA (total N=439).  
RESULTS: 
Of 393 with both VIA and hrHPV data, 89 (22.6%) had evidence of cervical hrHPV. 
hrHPV prevalence varied by year (29.6% in 2013, 17.4% in 2017; P=.004). Of these 89, 
37 were reported with specific subtypes, of which 26 (70.3%) were HPV16, 1 (2.7%) was 
mixed HPV16/18, and 2 (5.4%) were HPV18. HPV16 was less common in 2013 (12/20 
[60%]) than in 2017 (15/17 [88.2%]; P=.054). VIA was abnormal in only 10% of women 
with positive hrHPV subtype infection (sensitivity); specificity was 95.4%. Predictive 
values of positive and negative tests were 39.1% and 78.4%, respectively.    
CONCLUSION: 
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These data suggest that exclusive VIA use may not detect many women with persistent 
infection and may be insufficient for screening. Real-time nucleic acid hrHPV detection 
may be superior, coupled onsite treatment and an effective HPV immunization program.  
Introduction 
Cervical cancer is one of the most studied and best-understood malignancies.  
Oncogenic (“high risk”) human papillomavirus (hrHPV) subtypes are recovered in 95%-
100% of cervical cancer specimens and have been established to cause most cases of 
cervical carcinoma1-11. Though cervical cancer is one of the most preventable and 
treatable cancers, it remains the fourth leading cause of cancer mortality in women 
worldwide12. Industrialized countries have reduced cervical cancer mortality through 
screening and over 80% of cervical cancer mortality currently occurs in low- and middle-
income countries13-18.  In 2010, cervical cancer was the fourteenth most frequent cause of 
cancer in US women and the mortality rate was 2.4/100,00019.  
In contrast, in low and middle-income countries, cervical cancer remains a 
leading cause of death despite the existence of effective and modestly priced screening, 
diagnosis and treatment. The Latin American and Caribbean regions are home to just nine 
percent of the world population, but bear approximately 16% of the world burden of 
cervical cancer mortality14,16,17,20,21.  In Guatemala understanding hrHPV prevalence 
cervical cancer incidence and related mortality is difficult due to the low resources 
available to determine HPV prevalence and accurate data documenting incidence and 
mortality7,8. As a result, these have been imputed from surrounding countries, and from 
testing in specific areas. 
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Considerable differences in economic status and access to health care, present 
significant barriers to indigenous women in Guatemala. Over half (51%) of the 
population in Guatemala is documented as indigenous22-24; 90% of indigenous persons 
are classified as poor, or extremely poor23,24. Indigenous communities, particularly the 
large Maya population, endure much shorter life expectancies, 17 years shorter than non-
indigenous groups22-24 a consequence, of inaccessible health care, among many barriers 
for this population. Health expenditures in 2014 were 2.3347% of GDP in Guatemala25, 
limiting health service expansion. In rural areas, there is a system for primary care 
consisting of 1,101 health posts employing a nurse, with varying access to mobile teams 
consisting of a physician, a nurse, and volunteers at the community level called “health 
facilitators” and “health guardians”26-29. 
To assess and address needs related to cervical cancer in underserved Guatemalan 
rural indigenous populations, visual inspection with acetic acid (VIA) has been proposed 
as it has in many underserved settings9,31-35. However, little is known of the prevalence of 
hrHPV oncogenic subtype infection in Guatemalan rural indigenous women, or 
effectiveness of VIA in identifying women with lesions suspicious for hrHPV , onsite 
“test-and-treat” strategies, and methods currently used to link them to specialized 
care7,8,33. To explore the prevalence of hrHPV subtype infection and the effectiveness of 
VIA in detecting hrHPV infection in this population, we analyzed anonymized data from 
women who were screened as part of a nonprofit organization’s efforts to provide 
services to this population.  
Methods 
VIA Screening Clinics 
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The VIA screening clinics took place in two weeks in 2013 and 2017, 
respectively, in six villages, two of which were visited twice. These villages were located 
in Baja Vera Paz, immediately north of the capital region, and Alta Vera Paz, just north 
of Baja Vera Paz (Figure 5). The villages included Rabinal and Campur (each visited in 
both 2013 and 2017), Cahabon and Santa Cruz, visited just in 2013, and Carchar and 
Tactic, visited in 2017 only. The VIA screening clinics were supported by two NGOs that 
partner to bring services to rural Guatemala (Partners for Surgery and Timmy Global 
Health in 2013 and Partners for Surgery 2017). The schedule of the VIA clinic was 
coordinated with the local communities arranging for space to provide the clinic. The 
schedule and availability of screening was announced by Promotoras de Salud (female 
Community Health Promoters) employed by Partners for Surgery, who visited the areas 
where the clinics would be held two to four weeks before the event took place. 
Promotoras encouraged local women to participate in VIA screening. All women 21-65 
years old denying pregnancy, presenting for and consenting to VIA testing were 
examined. 
VIA Methodology and Specimen Collection   
Guatemalan nurses who were undertaking the exam, both native Spanish 
speakers, obtained consent for the VIA screening. The nurses performing the exam had 
been trained during a governmental health department program and subsequently were 
hired by Partners for Surgery. Promotoras fluent in Q’eqchi and Mamean languages, the 
principal Mayan languages spoken in the region, translated for participants who were 
non-Spanish speakers. A separate consent for an additional sample for hrHPV nucleic 
acid testing used the form for a research study conducted by the National Cancer 
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Institute, National Institutes of Health (NIH). VIA was performed during a speculum 
exam to visualize the cervix just after collection of the specimen for hrHPV detection; a 
3%-5% dilution of acetic acid (vinegar) was applied to the cervix, which was not a 
painful procedure. Visualization of the squamocolumnar junction in the cervix, where 
multi-layer tissue composed of squamous cells joins one-layer columnar tissue, was 
required for interpretation of VIA. Abnormal precancerous tissue and HPV-related 
lesions were expected to become white in appearance when exposed to vinegar, the 
principle on which VIA is based35. Specimen collection for HPV subtype determination 
with hrHPV testing was done prior to vinegar application during the same speculum 
exam with a Dacron swab.   
High-Risk HPV Subtype Detection 
The specimen was stored in a transport solution until shipment to the NIH 
laboratory without refrigeration, where hrHPV testing was done using the	Hybrid Capture 
2 assay (HC2; Qiagen, Germantown, MD) to detect hrHPV nucleic acid. This testing 
characterized HPV subtypes collected during the 2013 screening clinic in Rabinal, 
including hrHPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 with the 
kit, and additional subtypes detected in the NIH laboratory including subtypes 32, 67, 81, 
and 114. For samples collected in 2013 from other villages, hrHPV positive results were 
characterized as such without further subtype characterization. For samples collected 
during the 2017 screening clinics, Cobas  HPV 4800 Amplification/Detection Kit (Roche 
Molecular Systems, Branchburg, NJ) to detect hrHPV including 16 and 18, and 12 pooled 
hrHPV subtypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). These were performed 
at the Palm Beach Pathology Laboratory (West Palm Beach, FL).   
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Treatment and Management of Women With Abnormal hrHPV and Results 
Cryotherapy was used according to ministry of health guidelines for lesions 
believed to be benign but precancerous, but a Partner for Surgery staff member referred 
each woman for care in the case of an exam revealing physical changes suspicious for 
cervical cancer. The woman was advised regarding the disease, the urgency for treatment 
and the facilities that provide such care in the capital, Guatemala City, or local private 
care. Demographic data, VIA results and previous cervical screening history and results 
data were labeled with a patient identification number linked to the specimen 
identification for HPV subtype test, but was unlinked to any other patient identifiers. 
These de-identified anonymized data were forwarded to Florida International University 
investigators for analysis.  
In the 2013 clinics, there was no protocol for advising Partners in Surgery staff 
about hrHPV results or for confirming that the women referred actually attended 
specialized care. In the 2017 clinic, cytology results were provided to Partners in Surgery 
staff so that Promotoras de Salud could advise the women with abnormal results of the 
need to seek specialized care, and where to seek such care for sliding scale or reduced 
prices.   
Statistical Analysis 
 Data were entered into Excel files and analyzed using Epi Info for Windows 
Version 3.5.4 (Centers for Disease Control and Prevention, 2012, Atlanta, GA). 
Prevalence ratios (PRs) were used as estimates of relative risk when assessing the 
strength of associations; 95% confidence intervals (95%CIs) were used to assess 
precision of estimates and for statistical significance testing in bivariate analysis. 
52 	
Medians were used as measures of central tendency for continuous variables, and the 
Kruskal-Wallis test for two groups, which has no assumption of normal distribution, was 
used for statistical significance testing. For analyses of categorical variables, the Χ2 was 
used if all expected cells>5; otherwise, Fisher exact two-tailed test was used. Sensitivity 
of VIA relative to hrHPV testing was calculated as the proportion of hrHPV positive tests 
for which VIA was abnormal, and specificity, as the proportion of hrHPV negative tests 
for which VIA was abnormal36.   
Results 
Human Participant Ethical Review 
 The Florida International University Institutional Review Board reviewed the 
research and considered it a secondary analysis of de-identified data (not human 
participant research). 
Population  
 Although 439 women consented to both tests, VIA results were available for only 
413 women (189 in 2013 and 224 in 2017) and hrHPV results, only for 394 (170 in 2013 
and 224 in 2017); results for both VIA and hrHPV results were available for 393. Most 
(76%) were aged 30 years or older (median=36 years; interquartile range [IQR]=30-43 
years); 104 (62.3%) reported at least one prior cervical cancer cytological screening with 
a Papanicolaou (“pap smear”) test. Just over half were interviewed in Mayan languages 
(over 80% of those in Q’eqchi). Almost half were interviewed in Spanish.  
VIA and hrHPV Results 
Of the women with both VIA and hrHPV subtype test results, 23 (5.9%; 
95%CI=3.8%-8.8%) had abnormal VIA; 89 (22.6%; 95%CI=18.7%-27.2%) had nucleic 
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acid from at least one hrHPV subtype detected; 65.1% of women with hrHPV subtype 
infection were aged over 29 years, ranging from 30-58.  Proportions of VIA exams that 
were abnormal did not differ significantly by year (7.2% in 2013, 4.9% in 2017), but 
hrHPV prevalence varied significantly by year (50 of 169 [29.6%] in 2013, 39 of 224 
[17.4%], 2017; P=.004). Of these 89 with hrHPV, 37 were reported with specific 
subtypes, of which 26 (70.3%) were HPV16, 1 (2.7%) was mixed HPV16/18, and 2 
(5.4%) were HPV18 (Figure 6). HPV16 was less common in 2013 (12/20 [60%]) than in 
2017 (15/17 [88.2%]; P=.054).      
Sensitivity of VIA for detection of hrHPV in 2013 and 2017 were almost identical 
at about only 10.0% (Table 2). The association between abnormal VIA and hrHPV 
detection was higher in 2017 than in 2013. In all combined, patients with abnormal VIA 
were about 1.8 times as likely to have hrHPV nucleic acid detected than patients who had 
normal VIA (P=.05).  VIA specificity was 95.4%, with normal VIAs in over 95% of 
patients without hrHPV infection. VIA predictive positive and negative values for hrHPV 
were 39.1% and 78.4%. In the 2017 screening, one woman aged 47 years who had had 
cryotherapy three years before had a cervical tumor visible without magnification or 
acetic acid. 
Discussion 
Indigenous women in six rural villages in Guatemala had a moderately high 
prevalence of cervical hrHPV infection. Typing of subtypes among hrHPV-infected 
women was only done in about a third; distribution of subtypes differed somewhat by 
year. In 2017, using an assay that does not detect some of the subtypes reported in 2013, 
the prevalence was lower, with a higher proportion of infections due to HPV16 and 18 
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and lower proportion due to “pooled” subtypes. As a result, HPV 16, 18 and 31 
contributed to relatively low proportions of infections. However, when restricted to 
results from villages for which hrHPV samples were typed, about 70% of infections were 
due to subtypes most likely to cause persistent infection and progress to cancer16,36.   
Untreated, many hrHPV infections spontaneously resolve, especially those in 
women less than 30 years of age37, who usually are recently infected. However, almost 
two thirds of our participants with hrHPV cervical infection were over 29 years of age in 
our study. Conversely, HPV 16 is associated with more rapid progression and younger 
cancer onset2. Even among women with less aggressive subtypes, in this population, 
where marriage occurs early in life, and parity is high, hrHPV infections in young women 
may be more likely to represent persistent, progressive processes heralding malignancy.  
Cyrotherapy has been largely abandoned in high-income countries because it has 
not been proven to completely remove abnormal tissue, and is considered of less value in 
treating abnormal cells within the cervical canal. Cryotherapy, without excluding cervical 
canal abnormalities – an area not evaluated during VIA – may not reduce risk for 
persistent infection. Cryotherapy can affect the transformation zone where chronic 
infection occurs, preventing adequate screening without colposcopy and endocervical 
canal biopsy and is of dubious value in post-menopausal women whose transformation 
zone migrates deeper in the os. Our data are insufficient to comment on the value of 
cryotherapy, which has been shown to increase regression to normal histology38.  
Limitations of this study include use of different assays for hrHPV detection, 
likely related to the narrower range of subtypes detected and lower proportion of tests 
positive in 2017. Conversely, lack of additional evidence of precancerous or cancerous 
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lesions in women tested in 2013 with hrHPV (because no tests, such as cytology, were 
done) leaves uncertain how many of these infections may have been clinically 
unimportant. Except for the one woman with cervical cancer after cryotherapy, no 
information was available on outcomes.  Despite these limitations, our study suggests that 
in this underserved population, hrHPV-based test-and-treat, without VIA and even 
cytology, may be the most cost-effective strategy to reduce cervical cancer burden39-41. 
Coupled with scale-up of HPV immunization, hrHPV test-and-treat may reduce the toll 
that cervical cancer continues to exact in these underserved women.  
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Figure 5. Villages in which visual inspection with acetic acid screening clinics were held 
2013 and 2017. 
	
61 	
 		
 
 
 
Figure 6. Distribution (proportions) of high-risk (HR) human papillomavirus (HPV) 
results by subtype, 2013 (50 of 169 specimens collected) and in 2017 (39 of 224 
specimens collected), Alta and Baja Vera Paz, Guatemala. 	
NOTE: In 2013, subtypes were only reported on specimens from one village (Rabinal), 
with all positive tests from other villages characterized as “pooled” high-risk subtypes. In 
2017, assay did not detect some subtypes, but HPV16 and HPV18 were reported from all 
villages.    	
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Table 2 
Sensitivity and Specificity of Visual Inspection With Acetic Acid (VIA) for Detection of 
hrHPV, Alta and Baja Vera Paz, Guatemala, 2013 and 2017, and 95% Confidence 
Intervals (95%CIs) and VIA Predictive Positive and Negative Values 
Sensitivity, Specificity, Predictive Values of Positive and Negative VIA Tests 
 
 
 2013 2017 Total 
Sensitivity 5/50 (10.0%) 
   95%CI=3.3%-21.8% 
4/39 (10.3%) 
95%CI=2.9% 24.2%   
9/89 (10.1%) 
95% CI=	4.7% 18.3% 
Specificity 112/119 (94.1%) 
95%CI=88.3%-97.6% 
178/185 (96.2%) 
95%CI=92.4%-98.5%   
290/304 (95.4%) 
95%CI=92.2%-97.4% 
Predictive 
Value of 
Positive 
5/12 (41.7%) 4/11 (36.4%) 9/23 (39.1%) 
Predictive 
Value of 
Negative 
112/15 (71.3%) 178.213 (83.6%) 290/370 (78.4%) 
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Table 3 
Association Between VIA and hrHPV Subtype Test Results in 2013, 2017 and Both Years 
Combined 
 
 hrHPV 
Prevalence 
Prevalence Ratio 
(95% CI) 
P 
2013 Abnormal VIA     5/12 (41.7%) 1.45  
(0.71-2.97) 
.42 
2013 Normal VIA 45/157 (28.7%)              
2017 Abnormal VIA      4/11 (36.4%)              2.21 
(0.96- 5.12) 
      .20 
2017 Normal VIA 35/213 (16.4%)   
Total Abnormal VIA 9/23 (39.1%) 1.81  
(1.05-3.1224)   
.05 
Total Normal VIA 80/370 (21.6%)   	
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Abstract 
 
OBJECTIVE:  This study compared the performance of visual inspection with acetic 
acid (VIA) within a screen-and-treat approach to oncogenic (high risk) human 
papillomavirus (hrHPV) testing relative to a “gold standard” of liquid-based thin-layer 
preparation for cytological cervical cancer screening examination in rural indigenous 
communities in Guatemala.  
METHODS: During six days in September 2017, trained nurses screened 224 women 
aged 23-58 years for cervical cancer with VIA. Specimens for cytology and hrHPV 
subtype testing were obtained from the cervix prior to VIA with spatula and cytobrush, 
and placed immediately into PreservCyt, a methanol-based transport solution. Sensitivity 
of VIA and HPV subtype testing were evaluated as proportions of women with abnormal 
cytology (excluding abnormal squamous cells of undetermined significance) that had 
abnormal VIA or hrHPV subtype test results. Specificity was assessed as proportion of 
women with normal cytology that had normal VIA and no hrHPV subtypes.    
RESULTS: Of 224 women tested, 221 had usable cytology specimens; of those, 10 
(4.7%; 95% confidence interval [CI]=2.3%-8.5%) had abnormal results, including one 
carcinoma and four high-grade and five low-grade squamous intraepithelial lesions. 
Eleven of 224 (4.9%; 95%CI=2.5%-8.6%) had abnormal VIA and 39 (17.4%; 
95%CI=12.6%-23.6%) had hrHPV subtypes detected. Sensitivity of VIA in identifying 
precancerous and cancerous lesions was 20.0% (95%CI=2.5%-55.6%); specificity was 
96.1% (95%CI=92.4%-98.3%). Sensitivity and specificity of hrHPV-subtype testing in 
identifying precancerous and cancerous lesions were 100% (95%CI=71.7%-100%) and 
88.7% (95%CI=83.9%-92.7%) respectively. A confirmed cancerous lesion was seen 
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using VIA in a patient who had had VIA and cryotherapy four years before. Positive and 
negative predictive values were 20.0% and 96.1%, and 30.3% and 100% for VIA and 
hrHPV testing respectively. 
CONCLUSIONS: VIA-based screening may not consistently identify all women at 
highest risk for cervical cancer. hrHPV subtype test-and-treat strategies, usable in the 
field in low-resource settings, may be preferable to VIA-based testing.  
Introduction 
 Cervical cancer incidence and mortality decline in high-income countries 
accompanied use of cytological screening1 but effective screening strategies in low- and 
middle-income countries (LMICs) remain elusive. Oncogenic “high-risk” human 
papillomavirus (hrHPV) subtypes cause most cases of cervical cancer, one of the best-
understood and preventable malignancies, and are present in 95%-100% of cervical 
cancer specimens2. Latin American and the Caribbean (LAC), home to just nine percent 
of the world population, bear approximately 16% of the world burden of cervical cancer 
mortality3. Lack of infrastructure for screening and treatment, particularly in remote rural 
populations, are important barriers to detection and treatment. Cervical cancer is believed 
to be the leading cause of cancer mortality among Guatemalan women aged 15-44 years4.  
In LMICs lacking consistent access to cervical cytology, including in LAC, visual 
inspection with acetic acid (VIA) with onsite cryotherapy have been widely adopted5. 
Significant challenges in training and implementation of VIA in Guatemala, accompanied 
by low reliability and acceptability, may have impacted public sector VIA screening 
coverage, which is estimated at 12% to 18%, augmented by non-governmental 
organizations to almost 40%6,7. VIA requires minimal equipment: acetic acid (diluted 
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vinegar, 3-5%), a light source and speculums to perform the exam. Although VIA does 
not allow examiners to “grade” lesions, examiners can treat visible acetowhite lesions 
with cryotherapy (ablation with liquid nitrogen) eliminating the need for multiple visits. 
The analysis described in this paper compared the performance of VIA to hrHPV subtype 
testing, relative to “gold standard” liquid-based thin-layer preparation cytology in rural 
indigenous communities in Guatemala.      
Methods 
Population 
 Women living in four rural majority indigenous communities (Rabinal, Tactic, 
Compur and Cahabon), villages in Alta and Baja Vera Paz, Guatemala, were invited to 
attend a VIA clinic at no cost by Partners for Surgery, a non-governmental organization 
which provides health services in rural villages including cervical cancer screening to 
women aged over 21 years. Local community health promotors employed by Partners for 
Surgery informed community members 14-21 days prior to the event. 
Design 
 Cross-sectional analysis of de-identified data collected during brief interviews of 
participants, and by VIA, cytological examination and HPV testing.  
Setting 
 Examinations took place in local health centers that allowed privacy for women to 
be interviewed assisted by bilingual Spanish-Mayan language interpreters, and examined 
by Guatemalan registered nurses trained in VIA. As women consented, a number was 
assigned to the cytology and hrHPV specimens and recorded on the VIA result form, to 
provide patients with results. Data were anonymized before release to researchers.   
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Liquid-Based Thin-Preparation Cytology and hrHPV Subtype Testing 
  Specimens for cytology and hrHPV subtype testing were obtained from the 
cervix prior to VIA with a spatula and cytobrush, and placed immediately into 
PreservCyt, a methanol-based transport solution.  Cytology using Thin Prep (Quest 
Diagnostics, Alameda, CA) and hrHPV nucleic acid amplification using the Cobas  HPV 
4800 Amplification/Detection Kit (Roche Molecular Systems, Branchburg, NJ) to detect 
14 hrHPV subtypes including 16, 18, 45, and 51 were performed at the Palm Beach 
Pathology Laboratory (West Palm Beach, FL). All results were provided to Partners for 
Surgery to distribute to patients. Women with abnormal cytology results were referred for 
diagnostic evaluation. Those with normal cytology and positive hrHPV testing were 
advised to have annual VIA.   
VIA and Cryotherapy 
A sterile disposable clear plastic vaginal speculum was inserted in the vagina and 
freshly prepared 4% acetic acid was applied to the cervix. After one minute, the cervix 
was inspected using a hand-held flashlight. If the squamocolumnar junction was 
visualized, VIA was considered adequate. VIA was considered positive when a well-
defined, dense whitened area with regular margins was visible at the squamocolumnar 
junction or the transformation zone. It was considered negative if the squamocolumnar 
junction was visualized but no acetowhite lesions5 were observed.  Cryotherapy (ablation 
with liquid nitrogen) was offered to women with acetowhite lesions. Women whose VIA 
examination suggested malignancy (raised, irregular acetowhite lesion, bleeding on 
contact) were referred to specialized care on the day of examination with VIA results and 
directions to government facilities that offer subsidized care. 
69 	
Data Analysis 
 Results from the liquid-based thin-layer preparation cytology were considered the 
“gold standard” to calculate sensitivity and specificity of VIA and hrHPV. Results with 
atypical squamous cells of unknown significance (ASCUS) were excluded from the 
analysis. VIA and hrHPV subtype test sensitivities were calculated as proportions of 
women with abnormal cytology specimens whose VIA or HPV test was abnormal or 
positive, respectively. Specificities for VIA and hrHPV testing were calculated as 
proportions of women with normal cytology specimens with normal VIA or hrHPV 
results. Prevalence of abnormal VIA exams and hrHPV tests among women with 
abnormal cytological examinations (excluding ASCUS with negative HPV) was 
compared to prevalence in women with normal cytological examinations. Prevalence 
ratios were used as estimates of relative risk; 95% confidence intervals (95%CIs) were 
used to assess precision of estimates, and along with Fisher exact two-tailed tests, for 
statistical significance testing. All analyses were performed with Epi Info v. 3.5.4 
(Centers for Disease Control and Prevention, Atlanta, GA).  
Human Participant Ethical Review 
 The Florida International University Institutional Review Board reviewed the 
research and considered it a secondary analysis of de-identified data (not human 
participant research). 
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Results 
Nurses screened 224 women aged 23-58 (median age=36; interquartile range=30-
43) years. Three (1.3%) had insufficient cells to perform liquid-based thin preparation 
cytological testing. Of the 221 with usable cytological specimens, 10 (4.7%; 95%CI: 
2.3%-8.5%) had abnormalities, including a carcinoma in a woman who had had VIA and 
cryotherapy in 2015, and five low-grade and four high-grade intraepithelial lesions 
(excluding eight with ASCUS). Among those 10, seven had had at least one previous 
VIA examination. Eleven (4.9%; 95%CI: 2.5%-8.7%) of the VIA examinations were 
abnormal, including the carcinoma. Five of the 11 with abnormal VIA, including the one 
with the lesion, were referred to specialized care, and four cryotherapy treatments were 
administered; two others were asked to return for cryotherapy but did not do so.  Fifty-
eight (25.9%) women had never had a pelvic exam; median age of women without a prior 
pelvic exam was 33 years (vs. 38 years in others; p=0.001).  
hrHPV subtypes were detected in 39 (17.4%; 95%CI: 12.7%-23.0%) women. 
hrHPV subtype testing detected all 10 (sensitivity=100%; 95%CI: 71.7%-100%) women 
with abnormal cytological examinations. VIA detected only 2 of 10 (sensitivity=20%; 
95%CI: 2.5%-55.6%). Specificities of hrHPV subtype testing and VIA were 181/205 
(88.7%; 95%CI: 83.9% 92.7%) and 194/202 (96.1%; 95%CI=92.4%-98.3%), 
respectively.  Median ages and numbers of children of women with and without VIA 
abnormalities or hrHPV subtypes, did not differ significantly (data not shown).  
Both abnormal VIA and positive hrHPV tests were associated with abnormal 
cytological results, but association with positive hrHPV tests was stronger and 
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statistically significant (Table 4). Positive and negative predictive values were 30.3% and 
100% for hrHPV testing and 20.0% and 96.1% for VIA. Cryotherapy was used to treat 
four women with abnormal VIA who did not have abnormal cytology or hrHPV.  
Discussion 
In this small study, VIA and hrHPV subtype testing had very different 
sensitivities (20% vs. 100%) relative to cytology. Of the two women with abnormal VIA 
and cytological examinations, one had had an abnormal VIA and cryotherapy before, and 
presented with a cancerous lesion. These findings suggest that the sensitivity of VIA for 
cervical cancer screening conducted by highly trained nurses in this setting may be low 
compared to hrHPV testing, and that VIA-guided cryotherapy may not always affect the 
course of precancerous lesions. VIA may not be as reliable in menopausal women, and 
hrHPV testing in younger women, but in this study, age did not affect either. hrHPV 
prevalence in Guatemala sex workers at STI clinics and in women at community health 
centers was 67.3% and 38.1% respectively8, higher than observed in our study population 
(17.0%), in which no variance was seen by age or parity, (which has been associated with 
higher persistence of hrHPV).  
This study had several limitations. Because abnormal cytology prevalence was 
low (4.7%), precision of sensitivity and hrHPV positive predictive values were low. The 
use of cytological testing as a “gold standard” may underestimate hrHPV testing 
specificity, since hrHPV persistence may precede cytological evidence of precancerous 
changes. The study did not confirm abnormalities with biopsy, requiring ASCUS 
exclusion. The screening was offered in only four communities. Many women traveled 
hours by foot to attend, suggesting that women screened may have been more interested 
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in screening than the general rural Maya population, and may not reflect population-level 
risk.  
Nevertheless, our study suggests that VIA-based screening may miss women with 
treatable precancerous lesions and points to the promise of point-of-care real-time nucleic 
acid hrHPV testing, concurring with the World Health Organization recommendation to	
use a strategy of ‘screen with an HPV test and treat’, over a strategy of ‘screen with VIA 
and treat’9. In rural India, this approach decreased advanced cervical cancer and related 
deaths by over 40%, without significant reductions using cytological or VIA-based 
screening in comparison groups10. Cervical cancer is an important cause of death in 
Guatemala.  Our findings suggest concerns with use of VIA alone for cervical cancer 
screening.  
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Table 4 
Associations Between Abnormal Visual Inspection With Acetic Acid (VIA) and Cervical 
Cytological Results, and Between Oncogenic (High-Risk) Human Papillomavirus 
(hrHPV) Results and Cervical Cytological Results, Excluding Samples With Atypical 
Cells of Unknown Significance (ASCUS) 
Screening Test Results for 
VIA and hrHPV Subtype 
Testing 
Number (%) positive in 
women with abnormal 
cervical cytological 
results 
Prevalence 
Ratio 
(95%CI)* 
Fisher 
Exact  
2-tailed  
p-value 
VIA Results    
Abnormal 2/ 10 (20.0) 5.1 (1.2-21.0)  
 
0.145 
Normal 8/203 (3.9)   
hrHPV Test Results    
Positive 10/33 (30.3) ----† <0.0001 
Negative 0/180  (0) † ----  
*95% confidence interval; †Denominator=0 (no false positives); undefined, cannot divide 
by 0  
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Abstract 
OBJECTIVE: To determine prevalence of cervical infection with oncogenic (“high-
risk” [hr]) human papillomavirus (HPV) in indigenous women participating in two visual 
inspection with acetic acid (VIA) cervical cancer screening events and identify factors 
associated with hrHPV cervical infection in participants.  
METHODS: De-identified Data collected by interview and assays during VIA cervical 
cancer screening events in 2013 (N=205) and 2017 (N=234) for indigenous women aged 
21-65 years in six villages in Guatemala. Cervical specimens were collected for nucleic 
acid amplification testing to detect hrHPV before VIA was conducted.  
RESULTS: Of 394 women with hrHPV results, 90 (22.8%) had nucleic acid from at 
least one hrHPV subtype detected, 48.3% of whom had infection with subtypes 16 or 18, 
the subtypes most likely to be associated with persistent infection and cancers.  Women 
aged less than 29 years or reporting less than four pregnancies were more likely to have 
hrHPV cervical infection (36.8%, 27.3%, respectively) than those who were older or 
reported more pregnancies (18.7; <.0001 and 17.9%; P=.025, respectively). Women who 
reported use of progesterone injections or implants were more likely to have hrHPV 
detected (31.9%) than those who used other or no contraception (19.5%; P=.013). When 
controlled for other factors in logistic regression, younger age, lower parity, progesterone 
injection or implant use, or examination in 2013, were independently associated with 
hrHPV infection.     
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CONCLUSION: The association of hrHPV infection with long-acting progesterone 
contraceptive use may reflect progesterone’s action as a co-factor promoting hrHPV 
persistence.     
Introduction 
Persistent cervical infection with several subtypes of human papillomavirus 
(HPV), (oncogenic or “high risk” [hr] HPV subtypes), have been recognized since the 
1980s to be necessary for the development of cervical cancer1. However, infection alone 
with hrHPV subtypes does not appear to be sufficient to cause progression to cervical 
cancer. Several “cofactors” for the development of cervical cancer have been identified, 
including low literacy, multi-parity, and history of sexual abuse, older age, low 
socioeconomic status, and in some cases, racial and ethnic minority group status2. 
Screening tests that detect lesions before they progress to cancer, a process that for 
women with normal cell-mediated immunity, can take years or even decades, can arrest 
the process1,2. As such, many of the demographic and socioeconomic “cofactors” appear 
to reflect lower access to health care and preventive services, when controlled for hrHPV, 
cervical cancer screening and linkage to specialized care2. Lower access in Guatemalan 
indigenous women is related to language barriers, since many indigenous women do not 
speak Spanish, the national language, but rather, indigenous, mostly Mayan languages, 
and to very high rates of poverty (with over 70% of indigenous people, over half of 
Guatemala’s population living in severe poverty)3,4. Disenfranchisement and 
marginalization of Guatemalan indigenous groups has coincided with much worse health 
outcomes than counterparts of European descent5.   
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 Biological factors have been investigated in other settings, particularly links to 
hormonal contraception, but their role in high-parity marginalized populations, believed 
to have less hormonal contraception exposure, remains less studied. The objective of this 
analysis was to estimate prevalence of cervical infection with hrHPV subtypes in 
indigenous women participating in visual inspection with acetic acid (VIA) cervical 
cancer screening activities in 2013 and 2017, and identify factors associated with hrHPV 
in participants.  
Methods 
VIA Screening Clinics 
Six villages were visited in two weeks in 2013 and in 2017, including in Baja 
Vera Paz, north of the capital region, and Alta Vera Paz, north of Baja Vera Paz. Rabinal 
and Campur were each visited in both 2013 and 2017. Cahabon and Santa Cruz were 
visited only in 2013 and Canchar and Tactic, in 2017 only. The VIA screening clinics 
were supported by two NGOs that collaborate to bring services to rural Guatemala 
(Partner for Surgery and Timmy Global Health in 2013, Partner for Surgery in 2017). The 
VIA screening clinic schedule was coordinated with the local communities to arrange for 
space to provide the clinic. Availability of cervical cancer screening and time and date 
were announced by Promotoras de Salud (female Community Health Promoters) 
employed by Partners for Surgery, who visited the areas where the clinics would be held 
two to four weeks before the event. Promotoras encouraged local women to participate in 
VIA screening. All non-pregnant women 21-65 years of age who attended the events and 
consented to VIA were examined. Women had a brief interview to obtain basic 
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information (e.g., age, parity, previous cervical cancer screening and treatment, 
contraception). 
VIA Methodology and Specimen Collection 
Nurses who performed the exam obtained consent for the VIA screening. 
Promotoras fluent in the principal Mayan languages spoken in the region, translated for  
participants who were not Spanish speakers. A separate consent for an additional sample 
for HPV nucleic acid amplification testing used the form for a research study conducted 
by the National Cancer Institute, National Institutes of Health (NIH) in 2013. In 2017, a 
separate consent sought an additional sample for HPV nucleic acid amplification testing 
and for cytological testing. VIA was performed during a speculum exam to visualize the 
cervix just after collection of the specimen for hrHPV detection; a 3%-5% dilution of 
acetic acid (vinegar) was applied to the cervix. Visualization of the squamocolumnar 
junction in the cervix, where multi-layer tissue composed of squamous cells joins one-
layer columnar tissue, was required for interpretation of VIA. Abnormal precancerous 
tissue and HPV-related lesions were expected to become white in appearance when 
exposed to vinegar, the principle on which VIA is based.6 Specimen collection for HPV 
subtype determination in 2013 and 2017, and in 2017, cytology sample, were obtained 
prior to vinegar application during the same speculum exam with a Dacron swab.   
High-Risk HPV Subtype Detection 
In 2013, the specimen was stored in a transport solution until shipment to the NIH 
laboratory without refrigeration, where hrHPV testing used the	Hybrid Capture 2 assay 
(HC2; Qiagen, Germantown, MD) to detect hrHPV nucleic acid. This testing 
characterized hrHPV subtypes 16, 18 and 11 “pooled” subtypes 31, 33, 35, 39, 45, 51, 52, 
80 	
56, 58, 59, and 68; additional subtypes detected in the NIH laboratory included 32, 67, 
81, and 114 for specimens collected in Rabinal in 2013. For other villages in 2013, no 
breakdown of hrHPV subtypes was provided. For samples collected in 2017, Cobas HPV 
4800 Amplification/ Detection Kit (Roche Molecular Systems, Branchburg, NJ) was used 
to detect hrHPV including 16 and 18, and 12 pooled hrHPV subtypes (31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66 and 68) at the Palm Beach Pathology Laboratory (West Palm 
Beach, FL).   
Treatment and Management of Women With Abnormal hrHPV and Results 
Cryotherapy was used according to ministry of health guidelines for lesions 
believed to be benign but precancerous. Partner for Surgery staff members referred 
women for care in the case of an exam revealing physical changes suspicious for cervical 
cancer. Women were advised regarding the disease, the urgency for treatment and the 
facilities that provide such care in  
the capital, Guatemala City, or local private care. Demographic and interview data, VIA 
results and previous cervical screening history were labeled with a patient identification 
number linked to the specimen identification for HPV subtype test (and cytology result in 
2017), but were unlinked to any patient identifiers.  
In the 2013 events, there was no protocol for advising Partners in Surgery staff 
about hrHPV results or for confirming that the women referred actually attended 
specialized care. In the 2017 events, cytology results were provided to Partners in 
Surgery staff so that Promotoras de Salud could advise the women with abnormal results 
of the need to seek specialized care, and where to seek such care for sliding scale or 
reduced prices.   
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Statistical Analysis 
 Data were entered into Excel files and analyzed using Epi Info for Windows 
Version 3.5.4 (Centers for Disease Control and Prevention, 2012, Atlanta, GA). 
Prevalence ratios (PRs) were used as estimates of relative risk when assessing the 
strength of associations between putative predictors and hrHPV infection; 95% 
confidence intervals (95%CIs) were used to assess precision of estimates and for 
statistical significance testing in bivariate analysis. The Kruskal-Wallis test for two 
groups, which has no assumption of normal distribution, was used for statistical 
significance testing for continuous variables. For statistical significance testing of 
categorical variables, the Χ2 was used if all expected cells >5; otherwise, Fisher exact 
two-tailed test was used. 
Human Participant Ethical Review 
 The Florida International University Institutional Review Board reviewed the 
research and considered the analysis of de-identified anonymized data forwarded to 
Florida International University investigators for analysis not human participant research. 
Results 
As was typical for this type of event, hundreds of women (N=205), and N=234 in 
2017; total N=439) attended the VIA clinics. Many came on foot from villages miles 
away, and waited up to 7-8 hours for screening. hrHPV results were available from 170 
women examined in 2013 in Campur, Rabinal, Cahabon and Santa Cruz, and 224 from 
women examined in 2017 in Campur, Rabinal, Carchar and Tactic (Total N=394, 89.4% 
of attendees); 90 (22.8%) had at least one hrHPV subtype detected. Of 60 positive hrHPV 
results from villages where specimens were characterized by subtype (Rabinal in both 
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years and Carchar and Tactic in 2017), 29 (48.3%) were subtypes 16 and 18, the subtypes 
most likely to be associated with persistent infection and cervical cancer.  Women’s ages 
ranged from 21 to 59 years (median=36 years; interquartile range [IQR]=30.0-43.0 
years).  Of 385 who gave information about contraceptive use (167 in 2013, 218 in 2017), 
most (234 [60.0%]) used some form of contraception. Data on language used during 
interview were available for 214 women of whom 48.1% were interviewed in Spanish. 
The proportion of women who reported no contraception was almost identical among 
women interviewed in Spanish (35.9%) and among those interviewed in Mayan 
languages (38.7%; P=.67). The most frequently reported contraception, used by 91 
(23.5%), was long-acting progesterone injection or implant; 86 reported surgical 
sterilization and 28 (7.1%), oral contraceptives. Almost 67% reported at least one “Pap” 
cytological screening test in the past.  
  hrHPV prevalence did not vary significantly by village in either year, ranging 
from 26.3% in Rabinal to 36.8% in 2013, and from 17.1% in Rabinal to 17.9% in 
Canchar, but was significantly higher in 2013 (30.0%) than in 2017 (17.4%); P=.003 
(Table 5). Women who were aged less than 29 years or who had had less than four 
pregnancies were also more likely to have hrHPV cervical infection. Women who 
reported progesterone injection or implant use were more likely to have hrHPV (31.9%) 
detected than those who used other or no contraception (19.5%; P=.013). When 
controlled for other factors in logistic regression, younger age, examination in2013, and 
progesterone implant or injection for contraception were independently associated with 
hrHPV co-infection (Table 6).     
Discussion 
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VIA is often considered a cervical cancer screening option for women with little 
or no access to care. Yet the majority of women tested as part of the screening activities 
described here reported prior cytological cancer screening and contraception (mostly 
prescription or surgical sterilization) use. Since early as the 1960s, as the use of oral 
contraceptives increased worldwide, the effect of exogenous steroid hormonal 
contraception began to be investigated as a possible co-factor in cervical cancer 
development.6 Studies focused on oral combined hormonal contraception, which was 
more widely used. Recently, long-acting reversible contraception delivered by implant, 
and less conveniently, by quarterly injection) has been promoted in LMICs where health 
care access may be difficult7.  
The association between hormonal contraception and cervical cancer has been 
increasingly investigated as cervical cancer cofactors with mixed results.  In contrast, 
behavioral factors have lessened in importance as cofactors, since they have been noted 
to only modestly increase risk of development of cervical cancer in women testing 
positive for hrHPV2. Looking beyond circumstantial risk and into genetic factors both of 
the woman and of hrHPV itself, may help elucidate the role of exogenous hormone use. 
In 1990, Herrero et al.8 demonstrated the association between long-term injectable 
progesterone contraception use and cervical cancer.  
Several issues in this analysis limit its generalizability. Like many clinic 
populations, rural populations that overcome significant barriers to attend a VIA clinic, 
and report prescription contraception and prior cytological examinations, as the 
populations described in this report may not represent the most marginalized populations, 
but rather, highly motivated individuals who greatly value health care. The possibility of 
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recall and social desirability bias is present, as lapses (particularly failure to attend 
appointments for injectable progesterone) may be difficult to remember, and long-acting 
contraception is energetically promoted to marginalized populations.7 The prevalence of 
hrHPV infection was high overall, but much higher in 2013. It is unclear why prevalence 
overall declined in 2017, although the higher number of attendees may reflect a change 
towards broader representation of lower-risk individuals.  
Despite these limitations, this analysis demonstrates an association, independent 
of age and parity between long-term progesterone exposure and hrHPV infection, with 
higher risk in these users than in women who report not using any contraception and 
women using contraception other than progesterone-based methods. Essential to 
women’s empowerment is fertility control, of particular importance in countries where 
women, particularly women of indigenous background, experience barriers, including 
discrimination5, in healthcare access. The long-term delivery systems allow for less need 
to access health care and pharmacy, cost and greater privacy in their contraception use. 
Beyond the fertility control, progesterone-only products reduce or eliminate menstrual 
bleeding, decreasing monthly hygienic challenges and anemia.  
Recent studies have been able to describe the natural history of hrHPV infections, 
evaluate genetic components of hrHPV subtype persistence, and the effect on the cervical 
tissue of hormones such as estrogen and progesterone9,10. The analysis of multi-parity 
associated with increased risk for cervical cancer has suggested that high hormonal 
milieu effect cervical tissue changes occurring after a birth which result in increased 
exposure of the transformation zone where hrHPV infection occurs9,10. Chagas et al.9 in 
studying oral contraception and cervical cancer identified a gene polymorphism which, if 
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present, increases an oral contraceptive user’s risk for cervical cancer. Additionally, it is 
known that estrogen and progesterone stimulate HPV16 expression producing anti-tumor 
suppression by E6 and E7 oncogenes.9,10 Improved understanding of genetic interactions 
could help better define the risk for cervical cancer through specialized screening for 
women interested in use of hormonal contraceptives. Multiparity and hormonal 
contraception both increase women’s hormone exposure, endogenous (hormonal support 
of pregnancy) and exogenous (contraception), both may increase risk for cervical cancer 
by promoting expression of hrHPV, underscoring the importance of accessible 
reproductive health care that includes cervical cancer screening for underserved women 
in Guatemala.  
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Table 5 
Characteristic Associated With Statistically Significant Increased Risk of High-Risk (hr) 
Human Papillomavirus (HPV) Cervical Infections in Rural Indigenous Women in 
Guatemala Attending Visual Inspection With Acetic Acid Cervical Cancer Screening 
Clinics 
Characteristic Number with hrHPV 
Infections/Total Number 
with Factor (%)  
Prevalence Ratio  
(95% Confidence 
Interval) 
P-value 
Year, 2013 51/170 (30.0) 1.72 
1.19-2.49 
       .003 
Year, 2017 39/224 (17.4)   
Age less than 29 
years 
28/76 (36.8) 1.97 
(1.35-2.86) 
<.0001 
Age 29 or older 59/315 (18.7)   
Less than 4 
pregnancies 
50/133 (27.3) 1.43  
(1.05-2.23) 
.0253 
4 or more  
pregnancies  
37/207 (17.9) 
 
  
Progesterone 
Injectable or 
Implant User 
21/91 (31.9) 1.63  
(1.12-2.38) 
.013 
Progesterone 
Injectable or 
Implant Non-User 
58/297 (19.5)   
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Table 6 
Factors Associated With High-Risk Human Papillomavirus (hrHPV) Cervical Infection 
in Logistic Regression, Controlling for Examination in 2013, age Less Than 29 Years, 
Parity Less Than Four, and Progesterone Depot and Implant use, Confined to 387 
Women Without Missing Values in all Variables 
 
Factor Odds Ratio 
95%  
Confidence 
Interval 
P-Value 
Age less than 29 
years  1.92 1.02-3.60 0.0421 
Progesterone depot or 
implant use  1.80 1.04-2.12 0.0361 
Parity less than four  1.32 0.76-2.30 0.3233 
Examination in 2013  1.97 1.20-3.23 0.0077 
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VI: SUMMARY AND DISCUSSION 
 
Summary 
 
 These analyses of data collected in the Vera Paz regions of Guatemala provide 
insight into the state of cervical cancer screening programs for underserved rural 
indigenous women in the region. As previously noted, the health system is reliant upon 
NGOs to extend services into the remote areas of the country1. The NGO that conducted 
VIA exams is tasked with screening, and aside from onsite, immediate cryotherapy, has 
limited avenues to provide or secure further treatment.  In 2013, the evaluation of the 
VIA exam was a first look at hrHPV prevalence in the Vera Paz region. In 2009 Valles2 
reported there were no data available regarding the burden of high-risk (hr) human 
papillomavirus (HPV) infection in Guatemala, and the estimated coverage of cytological 
testing (with Papanicolaou tests [“pap smears”] or liquid preparations) was less than 
10%.  Since then, hrHPV prevalence in Guatemalan women in the general and sex 
worker populations have been reported as 38.1% and 67.3%, respectively3; 17% of 
indigenous women in Santiago de Atitlan, Guatemala, had at least one hrHPV subtype 
detected in self-obtained samples4. In evaluating prevalence of hrHPV in the region, six 
communities participated in the screening, with a combined prevalence of over 22.8%, 
somewhat higher than the estimated prevalence of 16.1% in Latin America and the 
Caribbean that Bruni3 et al. reported.  
An age-adjusted evaluation by Bruni3 showed a peak in early adulthood, then a 
second peak in hrHPV infection in Central and South America at age 45, clearly 
emphasizing the need for lifelong screening. The small prevalence study in 2013 also 
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compared VIA to the hrHPV findings. Of the women examined during this activity only 
eight VIA exams were positive, and of the 42 positive hrHPV, only three of the women 
who tested positive had abnormal VIA exams. The 2013 study had unanswered questions. 
There was no comparison with cytology or pathology to confirm the presence of 
precancerous changes in chronic infections sought in the VIA exam.  
Of importance is the setting for examination; the nurses were using hand-held 
flashlights with varying light devices and used vinegar stored in equipment cases in the 
transport vehicles. Adequate light is required to visualize the changes made by acetic acid 
application. Each site used for VIA exams had difficulty providing privacy and women 
had to present in the morning, some not being seen until late afternoon.4 Heat exposure5 
could affect acetic acid composition, and cause burning and irritation. 
 In some studies, VIA sensitivity for high-grade cervical intraepithelial neoplasia 
(cancerous or very likely precancerous lesions) has ranged from over 50% to over 80%, 
varying by menopausal status6,7.  However, VIA only detected 20% of cytological high 
and low-grade lesions during the 2017 screening activity. The screeners were dedicated 
Guatemalan nurses trained in VIA examination, traveling monthly to rural areas of 
Guatemala to provide screening. They work in difficult conditions, in clinics that often do 
not have running water, or adequate exam tables. In the 2017 study, 17.0% of women 
presenting for VIA had positive nucleic acid amplification tests hrHPV. VIA had a 
sensitivity of 20% in identifying abnormal cytological findings (excluding atypical cells 
of unknown significance). In contrast, sensitivity and specificity of hrHPV in detecting 
precancerous and cancerous lesions were 100% and 88.6% respectively. In a large recent 
study in Tanzania, VIA sensitivity relative to cytological and HPV testing was 
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unacceptably low, and varied significantly by screener experience, HIV infection status 
and age8. 
 The VIA screening activities have the capacity to treat women with positive 
exams, onsite without requiring a return visit. During the 2017 VIA screening activity 
four women were treated with cryotherapy; all of the ones treated had normal cytology 
and negative hrHPV. Cryotherapy is recommended onsite to prevent losing women with 
positive tests to follow-up, in some LMICs as high as 80% of women with precancerous 
lesions do not receive treatment9. Missing the opportunity to treat prior to malignant 
disease substantially raises costs financially and in lives lost. Cervical cancer is a disease 
that affects women in the middle years of life; Yang et al.10 calculated years of life lost 
(YLL) and found in Latin America and the Caribbean region, cervical cancer YLL 
represent a larger contribution than tuberculosis, maternal conditions or AIDS. However, 
none of the cryotherapy treatments were provided to women with evidence of 
precancerous lesions or persistent hrHPV infection. 
 The data suggest that the prevalence of hrHPV infection is high in this region of 
Guatemala, where access to screening programs is dependent upon mobile units 
supported by NGOs working independently or contracted by the Ministry of Health1. 
Poor indigenous women have high risk for cervical cancer primarily due to lack of 
screening resources, but also in the socio-demographic milieu of marginalization and 
isolation. Their high fertility rates have been established to contribute possible as a co-
factor in risk in cervical cancer11. This region is one of the poorest in Guatemala, with 
limited road system; Owen12 in 2009 analyzed Alta Vera Paz and found the total network 
consisted of 4.1% paved roads, 31.3% unpaved roads with 64.5% identified as trails. This 
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clearly demonstrates the remoteness of the area. Long identified barriers to cancer 
screening and treatment include rural residency, poverty and being uninsured13,14 
characteristics shared by many indigenous women in Guatemala in this region. In 2006 a 
qualitative study in Rabinal, Baja Vera Paz, one of the six communities participating in 
the VIA screening in 2013 and 2017, identified language and transportation as barriers to 
care, and noted that traditionally women first consult their husbands for their own health 
care and health care of the children15. These practices delay care and demonstrate the 
importance of education and community support of VIA screening. Empowering women 
by increasing their independent access to screening, and identifying and addressing 
beliefs that serve as a barrier to screening will help to provide acceptable screening in the 
community. Research has found the importance of involving the community in 
partnership for developing acceptable strategies16 to involve women in screening and also 
understanding the recommendation for continued surveillance for life. Moreover, in 
general, women (particularly in crowded settings with low privacy), like indigenous 
women in Atitlan, Guatemala, prefer self-obtained noninvasive specimen collection4  
 Screening will require more reliable strategies than VIA. VIA in this study fell 
short of expectations, but could be significantly enhanced or replaced with hrHPV 
subtype real-time testing onsite17. Self-sampling acceptability has been investigated in a 
small indigenous community in Guatemala and in other communities worldwide4,18. The 
authors determined that women preferred the self-sampling to an exam by physician, with 
95% of the indigenous participants completing the study. Findings in the New Delhi 
study suggested that “self-HPV sampling compares favorably with physician-sampling 
and cytology. Rapid, affordable, HPV self-test kit can be used as the primary method 
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of cervical cancer screening in low-resource situations18. These studies offer a sampling 
method preferable to the pelvic exam in this indigenous community. Reserving VIA, pap 
and colposcopy for women identified as high risk due to hrHPV infection would conserve 
resources. A rapid, affordable, HPV self-test kit can be used as the primary method of 
cervical cancer screening in low-resource situations. 
Theory of Planned Behavior 
 Some of the findings of the studies in this dissertation stand in contrast to the 
hypotheses, and even to the basic understanding of the cultural and social barriers to 
accessing women’s health care, but they are amenable to explanation by the Theory of 
Planned Behavior. Although most women chose to be interviewed in their community’s 
Mayan language, suggesting low acculturation, many of the cultural barriers assumed to 
occur in these communities were not identified. The majority of women accessing VIA 
reported previous cytological evaluation. Most (60.0%) reported contraceptive use. 
Clearly, their attendance at an event requiring hours of walking to arrive in the early 
morning and hours of waiting to be seen suggests that this group utilizes and values 
women’s health services. In fact, the proportion of VIA clinic participants who reported 
modern contraceptive method use was substantially higher than the proportion of married 
women at the national level reporting modern contraceptive use in the population-based 
2015 Guatemala Demographic and Health Survey (48.9%)19. It was also far higher than 
the proportion reported in a recent study of contraceptive use by women living in poverty 
in five Central American countries for Guatemala (27.5%)20. In that study, Guatemala’s 
poorest women had the second lowest level of contraceptive use of the five countries 
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assessed, which ranged from 15.3% in Panama to 82.2% in Nicaragua. This same study 
identified indigenous ethnicity as a strong predictor of failure to use modern 
contraceptive methods.  
 
In comparing the women attending the 2013 and 2017 VIA clinics to the women 
described in those reports, the Theory of Planned Behavior is instructive (Figure 2). 	 The 
work of community health promoters is the first step towards creating attitudes consistent 
with accepting cervical cancer screening. Their visible participation in recruitment, 
organizing and implementation of the activity normalizes the exam, and the numbers of 
women that attend each VIA clinic further reinforce the attitude that this is a valuable and 
desirable service.  As dozens of neighbors of all ages attend the activities, the subjective 
norm shifts to acceptance by the community, including by male partners, of the need for 
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an intrusive examination to preserve health and prevent deaths of wives and mothers. 
Finally, the ownership of the activity by the community, familiarity of the setting, service 
availability at no cost, and presence of community translators and facilitators affirms 
women’s perceived behavior control, in a setting of considerable peer support.   
This process, which begins with understanding screening and acceptance by the 
community allows women to seek screening for cervical cancer by intention21 and 
participation in a community-screening event, has women supporting each other.  
However, this activity is only as successful in prevention of cervical cancer as the 
efficacy of the screening method, and the linkage to effective care for women found to 
have precancerous or cancerous lesions. Identifying appropriate screening schedules and 
more reliable, cost-effective methods is a first step in adequate surveillance and improved 
estimates of cervical cancer incidence and mortality in indigenous populations and is vital 
to reducing the mortality associated with cervical cancer in this population. Screening 
ages have been evaluated for the greatest lifetime risk for cervical cancer reduction 
potential22. The natural history of hrHPV in immunocompetent women provides for 
intermittent screening, and the mean age of women with invasive cervical cancer is 50 
years, as estimated by Baseman and Koutsky23. VIA is known to have decreased 
sensitivity in older24,25 women, who at higher risk due to age, require a better screening 
tool and should be targets of screeners. 
 Guatemala struggles to provide cervical cancer-screening services to women; in 
200826 it was estimated that only 40% of women had ever been screened. Self-HPV 
sampling compares favorably with physician sampling and cytology and clearly must be 
pursued. However, Chary followed women referred for specialized diagnostic testing and 
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treatment for cervical cancer and found that inadequate equipment, equipment in 
disrepair and understaffing constrained the system, reporting 1200-1700 patients on a 
waiting list for radiation therapy27. The lack of treatment options poses the question of 
health ethics: is screening and diagnosis in communities without access to treatment 
inconsistent with the aim of screening. The persistent determination is that infrastructure 
for screening and linkage to care is poor in many LMICs as in Guatemala. The strategy of 
utilizing a proven – not perfect – tool such as cytology may not be attainable at present 
for marginalized populations in LMICs but hrHPV testing may be.  
Infrastructure development for cancer registries would help define the extent of 
the problem, as current incidence and mortality estimates are unreliable28 29 particularly 
for indigenous women. Cervical cancer represents 36% of new cancers being treated in 
201227 per Instituto de Cancerología (INCAN) patient registry, which also estimates only 
one third of patients initiating treatment complete therapy. Very often, the diagnosis of 
cervical cancer in members of marginalized populations is in later stages requiring 
specialized equipment, surgery and expensive chemotherapy or radiation therapy. This 
places considerable strain on the system as well as on families to little gain. Cervical 
cancer is predicted to increase by 75% in the region by 202524, threatening a crisis in 
indigenous women’s survival. 
 Root cause analysis of cervical cancer screening problems would center the 
discussion on infrastructure, not only to screen, but also to include streamlining linkage 
from screening to definitive diagnosis to treatment to cure. Awareness of risk for cervical 
cancer and understanding of the natural history of hrHPV infection is paramount to 
community and individual adherence with screening recommendations, and should be 
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incorporated by the local health promoters working with NGOs. For indigenous women, 
language, illiteracy, poverty, discrimination and violence serve to marginalize them 
placing these women at higher risk for cervical cancer, the theory of Gender and Power is 
a descriptor of circumstance of many Guatemalan women. 
Strengths and Limitations 
The strength of these studies is that it was a glimpse at hrHPV prevalence in a 
previously understudied population. Valles2 reported on prevalence comparing sex 
workers to “general population” (non-sex workers) women finding prevalence in women 
in the general population group did not decline with age as is expected; another small 
study in Atitlan indigenous women showed the acceptability of self-obtained samples.  
 Comparing VIA to cytology and hrHPV testing had not been done in Guatemalan 
indigenous populations prior to this study. VIA has been embraced by the Ministry of 
Health and therefore NGOs. While small, the study demonstrated a lower sensitivity than 
expected (22.2%) and a specificity of 96%. Conversely, with the strong showing of 
hrHPV testing (sensitivity and specificity: 100% and 88.6% respectively), real-time 
onsite hrHPV testing with or without VIA, reserving cytology and pathology for women 
with chronic hrHPV may save funds, time and staff resources, as a new infrastructure is 
established.  
 Limitations of the study include small sample sizes, with poor precision of 
estimates, low numbers of outcomes (e.g., one frank, invasive cancer after cryotherapy, 
nine low and high squamous cell ) and confining population to Vera Paz, so that this 
study cannot be assumed to represent indigenous women in Guatemala, the largest such 
population in Central America.  Clearly, the population’s level of commitment to health 
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and prevention, use of contraception and cervical cancer screening makes them 
unrepresentative. The possibility of recall and social desirability bias when discussing 
these issues, where there is a clearly stated priority to engage indigenous women in these 
activities, is high. 
 Conversely, these women, clearly extremely poor, underserved, marginalized 
people, prove that community-based screening for cervical cancer can attract them, and 
obviously more than once. Even if these women exaggerate their use of contraception and 
cervical cancer screening, that exaggeration itself clearly reflects a level of normalization 
(Figure 7) that is essential for population-based uptake of screening.  
Conclusions 
For next steps in promotion of cervical cancer screening (and contraception), 
these communities can serve as “early adopters”, partners in diffusion of innovation. 
Exploration of indigenous women’s understanding of cervical cancer and their 
acceptance of treatment, particularly in absence of significant symptoms, is essential in 
developing measures to ensure adherence to screening and treatment recommendations. 
Building on Dr Chary’s research on treatment at INCAN, following up with women 
referred for specialized diagnostic procedures and treatment from Vera Paz would help 
assess the effectiveness of cervical cancer screening. 
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